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INTRODUCTION
The oral route currently represents the most predominant and preferable route
of drug delivery. Unlike majority of parenteral dosage forms, it allows ease of
administration by the patient and it’s the natural, and therefore a highly convenient
way for substances to be introduced into the human body. Oral drug delivery systems
have progressed from conventional immediate release to site-specific delivery over a
period of time. Every patient would always like to have an ideal drug delivery
system possessing the two main properties that are single dose or less frequent
dosing for the whole duration of treatment and the dosage form must release active
drug directly at the site of action.
CONVENTIONAL DRUG DELIVERY SYSTEM
Oral drug delivery is the most widely utilized route of administration among
all the routes that have been explored for systemic delivery of drugs via
pharmaceutical products of different dosage forms.
The oral dosage form has survived due to
1. Relatively simple and inexpensive to make
2. Convenient for the patient
3. Technology is easy to adapt to changing needs of the drug substance
4. Simplifies the regulatory approval process.
Pharmaceutical products designed for oral delivery are mainly conventional
drug delivery systems, which are designed for immediate release of drug for
rapid/immediate absorption (Robinson JR Lee, 1987).
Limitations of the Conventional Drug Delivery System:
1) Drugs with short half-life require frequent administration, which increases
chances of missing the dose of drug leading to poor patient compliance.
2) A typical peak-valley plasma concentration-time profile is obtained which makes
attainment of steady state condition difficult.
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3) The unavoidable fluctuations in the drug concentration may lead to under
medication or overmedication as the steady state concentration values fall or rise
beyond the therapeutic range.
4) The fluctuating drug levels may lead to precipitation of adverse effects especially
of a drug with small therapeutic index, whenever overdosing occurs.
In order to overcome the drawbacks of conventional drug delivery systems,
several technical advancements have led to the development of controlled drug
delivery system that could revolutionize method of medication and provide a number
of therapeutic benefits (Chien, 1992).
CONTROLLED DRUG DELIVERY SYSTEM (CDDS)
Over the years, as the expense and complications involved in marketing new
drug entities have increased with concomitant recognition of the therapeutic
advantages of controlled drug delivery, greater attention has been focused on the
development of modified release dosage forms.
Modified release systems have been developed to improve the pharmacokinetic
profiles of active pharmaceutical ingredients (APIs) and patient compliance, as well
as reducing side effects. Oral modified release delivery systems are most commonly
used for 1) delayed release (e.g., by using an enteric coating); 2) extended release
(e.g., zero-order, first-order, biphasic release, etc.); 3) programmed release (e.g.,
pulsatile, triggered, etc.) and 4) site specific or timed release (e.g., for colonic
delivery or gastric retention). Extended, sustained or prolonged release drug delivery
systems are terms used synonymously to describe this group of controlled drug
delivery devices, with predictability and reproducibility in the drug release kinetics.
Delayed release dosage forms are distinguished from the ones mentioned above as
they exhibit a pronounced lag time before the drug is released. Oral extended release
dosage forms offer the opportunity to provide constant or nearly constant drug
plasma levels over an extended period of time following administration. Extended
release DDS include single-unit, such as tablets or capsules, and multiple-unit dosage
forms, such as mini tablets, pellets, beads or granules, either as coated (reservoir) or
matrix devices.
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Controlled Release
Controlled release systems designed to maintain plasma levels in therapeutic
range and thus minimize the effects of such problems. Furthermore; controlled
release systems reduce the dosing frequency, thereby improving patient compliance
and therapeutic efficacy (Christopher et al., 2005).
Sustained Release
Drug products that provide “extended” or “sustained” drug release appeared
as a major class of dosage form. Many terms as sustained-release, sustained-action,
prolonged- action, controlled-release, extended-release, timed-release, and long-
acting have been used to describe product types and features. For the most part, these
terms are used to describe orally administered dosage forms, whereas the term rate-
controlled delivery is applied to certain types of drug delivery systems in which the
rate of drug delivery is controlled by features of the device rather than by
physiological or environmental conditions as gastrointestinal pH or drug transit time
through the gastro intestinal tract (GIT).
Modified-release
This term has come into general use to describe dosage forms having drug
release features based on time, course, and/or location which are designed to
accomplish therapeutic or convenience objectives not offered by conventional or
immediate-release forms.
Extended-release
Extended-release dosage form is one that allows a reduction in dosing frequency
to that presented by a conventional dosage form.
Delayed-release
Dosage form is designed to release the drug from the dosage form at a time after
administration. The delay may be time- based or based on the influence of
environmental conditions, as gastrointestinal pH.
ABSORPTION WINDOWS
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Some drugs display region-specific absorption that can be related to
differential drug solubility and stability in different regions of the intestine as a result
of changes in environmental pH, degradation by enzymes present in the lumen of the
intestine or interaction with endogenous components such as bile. Active transport
mechanisms for drugs involving carriers and pump systems have been well
described. Compounds such as ACE inhibitors and certain antibiotics exploit peptide
transporters. The importance of P-450 metabolism in the intestinal mucosa has now
been recognized. The iso form P4503A4 (CYP3A4) is dominant in ‘gut wall’
metabolism and different levels are found in different regions of the intestine. The
absorption of drugs can also be limited by efflux mechanisms, especially if
compounds are lipophilic in nature. The secretory transporter P-glycoprotein located
on the mucosal surface of epithelial cells is responsible for the low and variable
bioavailability of various compounds (e.g.-propranolol, felodipine) some drugs can
be substrate for both CYP3A4 and P-glycoprotein (cyclosporine, itraconazole). In
theory, it should be possible to inhibit efflux and metabolism processes by the use of
inhibitors, but such agents are not usually without their own pharmacological effects.
The inhibitory effect of grapefruit juice toward intestinal CYP450 is a well known
example.
Today, it is possible to assess regional differences in intestinal drug
absorption by conducting non-invasive human drug absorption (HDA) study using a
remote controlled delivery capsule. Gamma scintigraphy is used for real-time
visualization of capsule location and a radiofrequency signal is used to activate the
capsule at the target site. For example, in order to determine the bioavailability and
pharmacokinetic profile of faropenem daloxate (a prodrug of broad spectrum
antibiotic), this drug was delivered in a particulate form to the proximal small bowel,
distal small bowel or ascending colon. The pharmacokinetic profiles for delivery to
the two sites in the small intestine were similar and comparable to those for a
reference tablet. Significant absorption was also seen after delivery to the colon, but
the area under the curve (AUC) and the maximum plasma concentration (Cmax)
values were markedly reduced (Washington et al., 2001)
Concept of absorption window
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Drug exhibiting absorption from only a particular portion of GI tract or
showing difference in absorption from various regions of GI tract are said to have
regional variability in intestinal absorption. Such drugs show absorption window
which signifies the regions of GI tract from where absorption primarily occurs.  Drug
released from the CRDDS after the absorption window has been crossed goes waste
with no or negligible absorption occurring (Figure 1). This phenomenon drastically
decreases the available drug for absorption, after release of drug from CRDDS. The
CRDDS possessing the ability of being retained in the stomach are called GRDDS
and they can help in optimizing the oral controlled delivery of drugs having
absorption window by continuously releasing drug prior to absorption window, for
prolonged period of time thus ensuring optimal bioavailability.
Figure1: a) Conventional drug delivery system, (b) GRDDS.
GASTRORETENTIVE DRUG DELIVERY SYSTEMS
Gastro retentive dosage forms are drug delivery systems which remain in the
stomach for an extended period of time and allow both spatial and time control of
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drug liberation. Basically, gastro retentive system retains in the stomach for a
number of hours and continuously releases the incorporated drug at a controlled rate
to preferred absorption sites in the upper intestinal tract. The retention of oral dosage
forms in the upper GIT causes prolonged contact time of drug with the GI mucosa,
leading to higher bioavailability, and hence therapeutic efficacy, reduced time
intervals for drug administration, potentially reduced dose size and thus improved
patient compliance. Therefore, Sustained release DDS possessing gastric retention
properties may be potentially useful.
ANATOMY AND PHYSIOLOGY OF THE GI TRACT
Figure 2: Structure of the gastrointestinal tract
Chapter 1 INTRODUCTION
Dept of Pharmaceutics 7 J.K.K. Nattraja College of Pharmacy
To comprehend the considerations taken in the design of GRDFs and to
evaluate their performance, the relevant anatomy and physiology of the
gastrointestinal tract must be fully understood. The basic Structure of the
gastrointestinal tract is shown in Fig 2.
The GIT consists of a hollow muscular tube starting from the oral cavity,
where food enters, the mouth, continuing through the pharynx, oesophagus, stomach
and intestines to the rectum and anus. Anatomical and physiological features of the
human GIT are given in Table 1.
Table 1: Anatomical and physiological features of the human GIT
Chapter 1 INTRODUCTION
Dept of Pharmaceutics 8 J.K.K. Nattraja College of Pharmacy
Stomach
The stomach is situated in the left upper part of the abdominal cavity under
the diaphragm, between the lower end of the esophagus and the small intestine, and
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is the most dilated part of the GIT. Its opening to the duodenum is controlled by the
pyloric sphincter. The stomach is divided into three anatomical regions (Figure 4).
i) Fundus
ii) Body and
iii) Pylorus (or antrum)
The proximal stomach consisted of fundus and body, which serves as a reservoir for
ingested materials, whereas the distal region (pylorus) is the major site of mixing
motions, acting as a pump to propel gastric contents for gastric emptying.(Tortora et
al., 1996; Wilson and Waugh, 1989).
Figure 3: Schematic illustration of the stomach anatomical structure
Small Intestine
The small intestine is composed of the duodenum, jejunum, and ileum. It
averages approximately 6m in length. The duodenum is the proximal C-shaped
section that curves around the head of the pancreas. The duodenum serves a mixing
function as it combines digestive secretions from the pancreas and liver with the
contents expelled from the stomach. The start of the jejunum is marked by a sharp
bend, the duodeno jejunal flexure. It is in the jejunum where the majority of
digestion and absorption occurs. The final portion, the ileum, is the longest segment
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and empties into the caecum at the ileocaecal junction. The small intestine has a
large surface area, which is comparable to the area of a basketball court, 463 m2.
This is the main reason it is the primary absorption site of water, ions, vitamins and
nutrients such as amino acids, fats and sugars. In addition, the digestion of fats,
peptides and sugars occurs in this segment of the gastrointestinal tract. The pH of the
small intestine is 6–7. The transit time in the small intestine of 361 h, is relatively
constant and is unaffected by food.
Large Intestine
The colon has some absorption properties of water and ions. Certain drugs
and especially peptide molecules are also absorbed. This is despite the lack of villi,
which leads to small surface area.
GASTRIC EMPTYING
The time a dosage form takes to traverse the stomach is usually termed the
‘gastric emptying rate’. Gastric emptying of Pharmaceuticals is highly variable and
is dependent on dosage form. The process of gastric emptying occurs during fasting
as well as fed states. However, the pattern of motility is distinct in the 2 states. In the
fasting state, it is characterized by an inter digestive series of electrical events that
cycle both through stomach and small intestine every 2 to 3 hours. This activity is
called the inter digestive myo electric cycle or migrating myo electric cycle (MMC),
which is further divided into following 4 consecutive phases (Figure 4) as described
by Wilson and Washington.
Figure 4: motility patterns of the GIT in the fasted state
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 Phase I (Basal phase) lasts from 40 to 60 minutes with rare contractions.
 Phase II (Pre burst phase) lasts for 40 to 60 minutes with intermittent action
potential and contractions. As the phase progresses the intensity and
frequency also increases gradually.
 Phase III (Burst phase) lasts for 4 to 6 minutes. It includes intense and
regular contractions for short period. It is due to this wave that all the
undigested material is swept out of the stomach down to the small intestine. It
is also known as the housekeeper wave.
 Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2
consecutive cycles.
The motor activity in the fed state is induced 5-10 min after ingestion of a meal
and persists as long as food remains in the stomach. It consists of regular and
frequent contractions. These contractions are not as severe as those in the third phase
of the fasted motility pattern. The G.I. Transit times of dosage forms in the various
segments of the G.I. tract are listed in Table 2.
Table 2: Transit times of various dosage forms across the segments of the GIT.
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Gastric pH
The gastric pH is influenced by many factors like diet, disease, presence of
gases or fatty acids, and other fermentation products (Rubinstein, 1990), age (Varis
et al., 1979), pathological  conditions  drugs, as well as intra- and inter-subject
variation. This variation in pH may significantly influence the performance of orally
administered drugs. Radiotelemetry, a noninvasive device, has successfully been
used to measure the gastrointestinal pH in humans. It has been reported that the mean
value of gastric pH in fasted healthy males is 1.7 ± 0.3 (Chung et al., 1986;
Dressman et al., 1990; Russell et al., 1993), while that of females was reported to be
slightly lower. On the other hand, in the fed state, the mean gastric pH in healthy
males has been reported to be between 4.3 – 5.4 (Dressman et al., 1990), and the pH
returned to basal level in about 2 to 4 hours.
About 20% of the elderly people exhibit either diminished
(hypochlorohydria) or no gastric acid secretion (achlorohydria) leading to basal pH
value over 5.0 (Varis et al., 1979). Pathological conditions such as pernicious anemia
and AIDS may significantly reduce gastric acid secretion leading to elevated gastric
pH. In addition, drugs like H2 receptor antagonists and proton pump inhibitors
significantly reduce gastric acid secretion.
Hence, the gastric pH is an important consideration when selecting a drug
substance, excipients, and drug carrier for designing intra gastric delivery systems.
FACTORS AFFECTING GASTRIC RETENTION OF DOSAGE FORMS
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 Density: Gastric retention time (GRT) is a function of dosage form buoyancy
that is dependent on the density of a dosage form which affects the gastric
emptying rate. A buoyant dosage form should have a density of less than that
of the gastric fluids floats. Since it is away from the pyloric sphincter, the
dosage unit is retained in the stomach for a prolonged period.
 Size: Dosage form units having a diameter of more than 7.5 mm are reported
to have an increased gastric residence time compared with those having a
diameter of 9.9 mm. Gastric retention time of a dosage form in the fed state
can also be influenced by its size. Small tablets are emptied from the stomach
during the digestive phase while large .size units are expelled during the
house keeping waves.
 Shape of dosage form: Different shapes (ring, tetrahedron, cloverleaf, disk,
string and pellet) displays different gastric retention times, due to their size
and geometry of the systems,.The tetrahedron resided in the stomach for
longer periods than other devices of a similar size; likewise extended gastric
retention was observed with rigid rings .Tetrahedron and ring-shaped devices
with a flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI)
have a better gastric residence time as compared with other shapes and had
been reported to have better GRT 90% to 100% retention at 24 hours
compared with other shapes.
 Single or multiple unit formulation: Multiple unit formulations show a
more predictable release profile and insignificant impairing of performance
due to failure of units, allow co-administration of units with different release
profiles or containing incompatible substances and permit a larger margin of
safety against dosage form failure compared with single unit dosage forms.
 Fed or unfed state: Under fasting conditions, the GI motility is characterized
by periods of strong motor activity or the migrating myoelectric complex
(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested
material from the stomach and, if the timing of administration of the
formulation coincides with that of the MMC, the GRT of the unit can be
expected to be very short. However, in the fed state, MMC is delayed and
GRT is considerably longer. It was concluded that as meals were given at the
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time when the previous digestive phase had not completed, the floating form
buoyant in the stomach could retain its position for another digestive phase as
it was carried by the peristaltic waves in the upper part of the stomach.
 Nature of meal: Feeding of indigestible polymers or fatty acid salts can
change the motility pattern of the stomach to a fed state, thus decreasing the
gastric emptying rate and prolonging drug release. (Timmermans et al, 1994)
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is
high in proteins and fats. (Marvola et al., 1989).
 Frequency of feed: The GRT can increase by over 400 minutes, when
successive meals are given compared with a single meal due to the low
frequency of MMC.
 Gender: Mean ambulatory GRT in males (3.4 ± 0.6 hours) is less compared
with their age and race matched female counterparts (4.6 ± 1.2 hours),
regardless of the weight, height and body surface.
 Age: Elderly people, especially those over 70, have a significantly longer
GRT.
 Posture: GRT can vary between supine and upright ambulatory states of the
patient.
 Concomitant drug administration: Anti cholinergics like atropine and
Propantheline, opiates like codeine and pro kinetic agents like
Metoclopramide and Cisapride (Mojave Ian et al., 1988).
 Biological factors: Diabetes and Crohn’s disease can affect the gastric
retention time.
DRUG CANDIDATES FOR GASTRIC RETENTION
Gastro retentive DDSs exhibiting controlled drug release are significantly
important for drugs which are:
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 Acting locally in the stomach (e.g. antibiotics against Helicobacter Pylori, antacids
and Misoprostol) (Burton et al., 1995; Fabregas et al., 1994; Oth et al., 1992;
Whitehead et al., 2000; Whitehead et al., 1996).
 Absorbed incompletely due to a relatively narrow window of absorption in the GIT,
such as Cyclosporin, Ciprofloxacin, Furosemide, L-DOPA, P-aminobenzoic acid and
Riboflavin. (Hoffman et al., 2004; Ichikawa et al., 1991a; Klausner et al., 2003d;
Levy and Jusko, 1966; Rouge et al., 1996).
 Unstable in the intestinal or colonic environment such as Captopril
 Exhibit low solubility at high pH values such as Verapamil HCl, Diazepam and
Chlordiazepoxide ( Elkheshen et al., 2004; Soppimath et al., 2001).
In general the group of drugs, that benefits from an oral application using a
gastro retentive DDS, includes analgesics, antibiotics, tranquilizers, diuretics,
antidepressants, vitamins, hormones, antacids and anti parkinsonian drugs
(Hoichman et al., 2004).
Gastro retentive DDS, on the other hand, are not suitable for drugs that may
cause gastric lesions, e.g., non-steroidal anti-inflammatory agents and drug
substances that are unstable in the strong acidic environment of the stomach. In
addition, gastro retentive systems do not offer significant advantages over
conventional dosage forms for drugs, which are absorbed throughout the
gastrointestinal tract (Talukder and Fassihi, 2004). It is recognized, however, that
there are many physiological constraints which may limit development of such
delivery systems.
APPROACHES TO GASTRIC RETENTION
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Various approaches have been pursued to increase the retention of oral
dosage forms in the stomach. The most common approaches used to increase the
gastric residence time of pharmaceutical dosage forms include
 Floating systems
 Swelling and expanding systems
 Bio adhesive systems
 Unfolding and modified- shape systems
 High density systems
 Others.
FLOATING SYSTEMS
Floating drug delivery systems (FDDS) have a bulk density less than gastric
fluids and so remain buoyant in the stomach without affecting the gastric emptying
rate for a prolonged period of time. While the system is floating on the gastric
contents (mechanism given in Figure 5), the drug is released slowly at the desired
rate from the system. After release of drug, the residual system is emptied from the
stomach. This results in an increased GRT and a better control of the fluctuations in
plasma drug concentration. However, besides a minimal gastric content needed to
allow the proper achievement of the buoyancy retention principle, a minimal level of
floating force (F) is also required to keep the dosage form reliably buoyant on the
surface of the meal.
Most floating systems reported in the literature are single unit systems, such
as HBS and floating tablets. The systems are unreliable and irreproducible in
prolonging residence time in the stomach when orally administered due to their all or
nothing empting process (Kawashima et al., 1991). On the other hand, multiple unit
dosage forms, such as hollow microsphere (micro balloons), granules, powder, and
pellets, are more suitable since they are claimed to reduce the inter- and intra-subject
variability in absorption and reduce the probability of dose dumping (Rouge et al.,
1997).
Figure 5: Mechanism of floating systems
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Types of floating drug delivery systems (FDDS)
Floating properties based on the mechanism of buoyancy are divided into:
1. Non effervescent systems with inherent low density or low density due to
swelling; and
2. Effervescent systems with low density due to gas generation and
entrapment.
Non- Effervescent Systems
A) Hydro dynamically Balanced Systems
These are single-unit dosage forms, containing one or more gel-forming
hydrophilic polymers. The polymer is mixed with drug and usually administered in a
gelatin capsule. The capsule rapidly dissolves in the gastric fluid, and hydration and
swelling of the surface polymers produces a floating mass. Drug release is controlled
by the formation of a hydrated boundary at the surface (Dubernet et al., 2004).
Continuous erosion of the surface allows water penetration to the inner layers,
maintaining surface hydration and buoyancy (Reddy et al., 2002) (Figure 6).
Chapter 1 INTRODUCTION
Dept of Pharmaceutics 18 J.K.K. Nattraja College of Pharmacy
Figure 6: Hydro dynamically balanced system
Hydro dynamically balanced systems (HBS) are designed to prolong the stay
of the dosage form in the gastro intestinal tract and aid in enhancing the absorption.
Such systems are best suited for drugs having a better solubility in acidic
environment and also for the drugs having specific site of absorption in the upper
part of the small intestine. To remain in the stomach for a prolonged period of time
the dosage form must have a bulk density of less than 1. It should stay in the
stomach, maintain its structural integrity, and release drug constantly from the
dosage form. The success of HBS capsule as a better system is best exemplified with
Chlordiazeopoxide hydrochloride. The drug is a classical example of a solubility
problem wherein it exhibits a 4000-fold difference in solubility going from pH 3 to 6
(the solubility of chlordiazepoxide hydrochloride is 150 mg/mL and is ~0.1 mg/mL
at neutral pH).
B) ALGINATE BEADS
Multi-unit floating dosage forms have been developed from freeze-dried
calcium alginate. Spherical beads of approximately 2.5 mm in diameter can be
prepared by dropping sodium alginate solution into aqueous solution of calcium
chloride, causing the precipitation of calcium alginate. The beads are then separated,
snap-frozen in liquid nitrogen, and freeze-dried at -40ºC for 24 hours, leading to the
formation of a porous system, which can maintain a floating force for over 12 hours.
These floating beads gave a prolonged residence time of more than 5.5 hours.
(Katayama et al., 1999).
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C) HOLLOW MICROSPHERES / MICROBALLONS:
Hollow microspheres loaded with drug in their outer polymer shelf were
prepared by a novel emulsion solvent diffusion method. The
ethanol/dichloromethane solution of the drug and an enteric acrylic polymer was
poured into an agitated solution of Poly Vinyl Alcohol (PVA) that was thermally
controlled at 40ºC. The gas phase is generated in the dispersed polymer droplet by
the evaporation of dichloromethane. The microballoon floated continuously over the
surface of an acidic dissolution media containing surfactant for more than 12 h in
vitro (Kawashima, 1992).
Floating micro particles based on low-density foam powder has been
proposed and its performance investigated in vitro (Streubel et al., 2002). The
floating micro particles were prepared with an oil-in-water solvent
extraction/evaporation method and were composed of polypropylene foam powder;
verapamil HCl as the model drug; and a controlled release polymer, Eudragit® RS,
EC or polymethyl methacrylate (PMMA). The micro particles were irregular in
shape and highly porous. Good in vitro floating behaviour was observed. The
increase in drug release was proportional to the drug loading and inversely
proportional to the amount of polymer and the release profile varied with varying the
polymer type.
Effervescent Systems (Gas-generating systems):
This approach provides floating drug delivery systems based on the
formation of CO2 gas. It utilizes effervescent components such as sodium
bicarbonate (NaHCO3) or sodium carbonate, and additionally citric or tartaric acid
(Rubinstein and Friend, 1994). Alternatively matrices containing chambers of liquids
that  turns into gas at body temperature could be used. Upon contact with the acidic
environment, a gas is liberated, which produces an upward motion of the dosage
form and maintains its buoyancy. A decrease in specific gravity causes the dosage
form to float on gastric contents.
These buoyant systems utilize matrices prepared with swellable polymers
such as methocel, polysaccharides (e.g., chitosan), and effervescent components
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(e.g., sodium bicarbonate, citric acid or tartaric acid).The system is so prepared that
upon arrival in the stomach, carbon dioxide is released, causing the formulation to
float in the stomach. Other approaches and materials that have been reported are a
mixture of sodium alginate and sodium bicarbonate, multiple unit floating pills that
generate carbon dioxide when ingested, floating mini capsules with a core of sodium
bicarbonate, lactose and polyvinylpyrrolidone coated with hydroxyl propyl
methylcellulose (HPMC), and floating systems based on ion exchange resin
technology, etc. (Rubinstein A et al., 1994; Stockwell AF et al., 1986).
Ichikawa et al developed a new multiple type of floating dosage system
composed of effervescent layers and swellable membrane layers coated on sustained
release pills. The inner layer of effervescent agents containing sodium bicarbonate
and tartaric acid was divided into 2 sublayers to avoid direct contact between the 2
agents. These sublayers were surrounded by a swellable polymer membrane
containing polyvinyl acetate and purified shellac. When this system was immersed in
the buffer at 37ºC, it settled down and the solution permeated into the effervescent
layer through the outer swellable membrane. CO2 was generated by the
neutralization reaction between the 2 effervescent agents, producing swollen pills
(like balloons) with a density less than 1.0 g/ml. It was found that the system had
good floating ability, independent of pH and viscosity and the drug released in a
sustained manner
Figure7. (a) A multi-unit oral floating dosage system. (b) Stages of floating
mechanism: (A) penetration of water; (B) generation of CO2 and floating ;( C)
Dissolution of drug.
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Table 3: List of drugs prepared as FDDS
S.No. DOSAGE FORM DRUGS
1. Microspheres
Metformin hydrochloride, ketoprofen, Aspirin,
Verapamil, Grisiofulvin, P-nitroanilline, Ibuprofen,
2. Granules Diclofenac sodium, Indomethacin, Prednisolone
3. Films Cinnarizine
4. Powders Several basic drugs
5. Capsules
Chlordiazepoxide HCl, Diazepam, Frusemide, L-
Dopa and  Benserazide, Misoprostol, Propranolol
6. Tablets/Pills
Phenytoin hydrochloride,5 fluoro uracil, Furosemide,
Ciprofloaxacin, pentoxyfillin, Atenolol,
Table 4: List of drugs which are marketed as FDDS
Brand name Drug Clinical Importance Dosage form
Madopar®
Levodopa
Benserazide
Parkinsonism Capsule
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Cytotec® Misoprostal Gastric ulcer Capsule
Valrelease® Diazepam Sedative –hypnotic Capsule
Conviron Ferrous sulphate Pernicious anemia Capsule
Liquid Gavison®
Al. hydroxide,
Mg. carbonate
Heart burn
Liquid alginate
preparation
Topalkan® Al-Mg antacid Antacid
Liquid alginate
preparation
Cifran OD® Ciprofloxacin Urinary tract infection Tablet
Oflin OD® Ofloxacin
Genital Urinary,
respiratory, Gastro-
intestinal infection
Tablet
Prolopa® Propranolol Hypertension Tablet
Amalgate
Flotacoat®
Amalgate Antacid Tablet
HaloTM Propranolol Hypertension Tablet
Raft-Forming Systems
Here, a gel-forming solution (e.g. sodium alginate solution containing
carbonates or bicarbonates) swells and forms a viscous cohesive gel containing
entrapped CO2 bubbles (Figure 8) on contact with gastric fluid. Formulations also
typically contain antacids such as aluminium hydroxide or calcium carbonate to
reduce gastric acidity. Because raft-forming systems produce a layer on the top of
gastric fluids, they are often used for gastroesophageal reflux treatment.
Figure 8: Schematic illustration of the barrier formed by a raft-forming system
Low-density systems
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SWELLING AND EXPANDING SYSTEMS
A dosage form in the stomach will withstand gastric transit if it is bigger than
the pyloric sphincter (Caldwell et al., 1988). However, the dosage form must be
small enough to be swallowed, and must not cause gastric obstruction either singly
or by accumulation. Thus, three configurations are required, a small configuration
for oral intake, an expanded gastroretentive form and a final small form enabling
evacuation following drug release.
The expansion of this type of DDS is generally due to the presence of
specific hydrogel formers, which after swallowing; drastically increase in size upon
contact with aqueous media. This increase in size prevents their exit from the
stomach through the pylorus. As a result, the dosage form is retained in the stomach
for a long period of time. These systems may be referred to as the “plug type
systems” since they exhibit a tendency to remain lodged at the pyloric sphincter.
Caldwell et al., 1988 proposed different geometric forms (tetrahedron, ring or planar
membrane (4-lobed, disc or 4-limbed cross form) of biodegradable polymer
compressed within a capsule.
BIOADHESIVE SYSTEMS
This approach is used to localize a delivery device within the lumen and
cavity of the body to enhance the drug absorption process in a site-specific manner
(Itoh et al., 1986). A bioadhesive can be defined as a substance with the ability to
interact with biological materials and is capable of being retained on the biological
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substrate for a period of time. Bioadhesion always occurs in the presence of water
(Andrews et al., 2009; Park and Robinson, 1985).
It involves the use of bioadhesive polymers that can adhere to the epithelial
surface of the GIT. These are usually macromolecular, hydrophilic gelling
substances with numerous hydrogen-bond forming groups, such as carboxyl,
hydroxyl, amide and sulfate groups (e.g., crosslinked polyacrylic acids, sodium
carboxymethyl cellulose (CMC), sodium alginate and carrageenan). A broad
spectrum of polymers was studied for their bioadhesive properties. It was concluded
that anionic polymers have better binding capacity than neutral or cationic polymers
(Lehr, 1994; Pardeep K. Gupta et al., 1990). The proposed mechanism of
bioadhesion is the formation of hydrogen – and electrostatic bonding at the mucus-
polymer boundary (Pardeep K. Gupta et al., 1990), although it is not yet clear. Rapid
hydration in contact with the muco-epithelial surface appears to favour adhesion.
UNFOLDING AND MODIFIED- SHAPE SYSTEMS
These are non disintegrating geometric shapes moulded from silastic
elastomer or extruded from polyethylene blends, which extend the gastric residence
time depending on size, shape and flexural modulus of the drug delivery device
(Caldwell, 1988a, 1988c; Cargill et al., 1988).
Devices with different geometrical shapes such as continuous solid stick,
tetrahedron, ring, cloverleaf, planer disk, string and pellet/sphere were investigated
(Caldwell, 1988c, 1988a, 1988b). These systems consist of at least one erodible
polymer (e.g., Eudragit® E, hydroxy propyl cellulose (HPC)), one non erodible
polymer (e.g., polyamides, poly olefins, polyurethanes), and a drug dispersed within
the polymer matrix. Cloverleaf, disk, string and pellet shapes were moulded from
silastic elastomer, while tetrahedron and rigid-ring shapes were fabricated from
blends of low-density polyethylene and ethylene: vinyl acetate copolymer. The
devices are compressible to a size suitable for swallowing within a capsule, and are
self-expandable to a size, which prevents their passage through the pylorus.
Furthermore, they are sufficiently resistant to forces of the stomach to prevent rapid
passage through the pylorus for a pre-determined period of time, and erode in the
presence of gastric juices.
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In vivo studies in beagle dogs have been performed to study the systems
physical characteristics, such as size, shape and flexibility on the gastric emptying
(Cargill et al., 1988), after they were folded and placed in a gelatin capsule. The
tetrahedron-shaped devices remained in the stomach for longer periods of time than
the other shapes, while strings and pellets were eliminated fairly rapidly.
Other shapes, which can be packed into gelatin capsules and increase in size
following unfolding, include Y-shaped systems   and sheet-like shaped devices.
HIGH DENSITY SYSTEMS
Sedimentation has been employed as a retention mechanism for pellets that
are small enough to be retained in the rugae or folds of the stomach body near the
pyloric region, which is the part of the organ with the lowest position in an upright
posture. Dense pellets (approximately 3g/cm-3) trapped in rugae also tend to
withstand the peristaltic movements of the stomach wall. With pellets, the GI transit
time can be extended from an average of 5.8–25 hours, depending more on density
than on the diameter of the pellets. Commonly used excipients are barium sulphate,
zinc oxide, titanium dioxide and IRO powder, etc. These materials increase density
by up to 1.5–2.4g/cm-3.
MAGNETIC SYSTEMS
This system is based on a simple idea: The dosage form contains a small
internal magnet and a magnet placed on the abdomen over the position of the
stomach. Ito et al., 1990 used this technique in the rabbits with bioadhesive granules
containing ultra fine Ferrite (γ-Fe2O3). This guided them to the esophagus with an
external magnet (~1700 G) for the initial 2 min and almost all the granules were
retained in the region after 2 hrs.
ADVANTAGES OF GASTRORETENTIVE DRUG DELIVERY SYSTEM
Floating drug delivery offers several applications for drugs having poor
bioavailability because of the narrow absorption window in the upper part of the
gastrointestinal tract. It retains the dosage forms at the site of absorption and thus
enhances the Bioavailability. These are summarized as follows.
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I. Sustained Drug Delivery
Sustained drug absorption from oral controlled release dosage form is often
limited due to short gastric retention time. However, GFDDS remain in the stomach
for several hours to their increased GRT. It has been suggested that due to their low
density than their gastric contents and relatively large size they do not pass through
the pylorus that has an opening of approximately 0.9-1.9cm. It has been observed
that major portion of drug relerases in the colon rather than the stomach in case of
modified release capsule. However, prolongation in the GRT may sustain the drug
.release behaviour.
II. Site Specific Drug Delivery
Drugs having absorption sites in the upper small intestine like furosemide and
riboflavin are typically formulated in the floating dosage forms. It has been reported
that absorption of furosemide takes place mainly through stomach followed by
duodenum. This characteristics of furosemide prompted scientists to develop a
monolithic floating system, which could prolong the GRT and thereby increase the
Bioavailability. GFDDS serves as an excellent drug delivery system for the
eradication of Helicobacter pylori, which causes chronic gastritis and peptic ulcers.
The treatment requires high drug concentrations to be maintained at the site of
infection that is within the gastric mucosa. By virtue of its floating ability these
dosage forms can be retained in the gastric region for a prolonged period so that the
drug can be targeted.
III. Absorption or Bioavailability Enhancement
Drugs that have poor Bioavailability because of site-specific absorption from
the upper part of the gastrointestinal tract are potential candidates to be formulated as
floating drug delivery systems, thereby maximizing their absorption. A significant
increase in the Bioavailability of floating dosage forms could be achieved.
IV. Fewer Doses: Creating once daily formulations for improved patient
compliance.
V. Improved plasma levels: Both extends plasma concentration levels and provides
a more linear release profile.
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VI. Better Bioavailability: Delivers the drug in the upper G.I. tract for optimal
absorption
VII. Less Irritation: The polymer matrix acts as a buffer between harsh drug
crystals and the stomach lining.
VIII. Fewer side effects: Keeps drugs out of the lower GI tract which can be
harmful to intestinal flora. Lower peak concentrations can also reduce adverse
pharmacological effects.
IX. Low risk inactive ingredients: Tablets are composed of well .understood
polymers from the FDA.s inactive ingredients list. This keeps the regulatory risks
and hurdles of the formulation to an absolute minimum.
X. Manufacturing ease: Tablets are made in standard high-speed tableting
equipment. No special tooling or engineering is required. The enables high quality,
consistent, rapid scale-up and technology transfer to our development and marketing
partners.
XI. Low cost: The ingredients used in these systems are commodity items, produced
in extremely large quantity and at very low cost.
Disadvantages of Gastroretentive Drug Delivery System
1. There are certain situations where gastric retention is not desirable. Aspirin
and non-steroidal anti-inflammatory drugs are known to cause gastric lesions
and slow release of such drugs in the stomach is unwanted.
2. Thus, drugs that may irritate the stomach lining or are unstable in its acidic
environment should not be formulated in gastroretentive systems.
3. Furthermore, other drugs, such as isosorbide dinitrate, that are absorbed
equally well throughout the GI tract will not benefit from incorporation into a
gastric retention system (Hou et al., 2003).
4. Gastric retention is influenced by many factors such as gastric motility, pH
and presence of food. These factors are never constant and hence the
buoyancy cannot be predicted exactly or accurately.
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5. Gastric emptying of floating forms in supine subjects may occur at random
and become highly dependent on the diameter. Therefore, patients should not
be dosed with floating forms just before going to bed.
6. High variability in gastric emptying time due to variations in emptying
process.
7. Unpredictable bioavailability.
LIMITATIONS
1. The major disadvantage of floating systems is requirement of a sufficiently
high level of fluids in the stomach for the drug delivery i.e. upto 400ml of
gastric fluids should be present for optimum buoyancy. However, this
limitation can be overcome by coating the dosage form with bioadhesive
polymers, which easily adhere to the mucosal lining of the stomach and
retain. The dosage form can be administered with a glass full of water (200-
250 ml) to provide the initial fluid for buoyancy.
2. Floating system is not feasible for those drugs that have solubility problems
in gastric fluids.
3. Drugs that are not stable at gastric pH are not suitable candidates to be
formulated as GRDDS.
4. Drugs that irritate the mucosa are not suitable candidates and should be
avoided to be formulated as GRDDS.
5. The drugs, which have multiple absorption sites in the gastrointestinal tract
and are absorbed throughout gastrointestinal tract, which under significant
first pass metabolism, are not desirable candidates.
6. Some drugs present in the floating system cause irritation to gastric mucosa.
7. Single unit floating capsules or tablets are associated with an all or none
concept, but this can be overcome by formulating multiple unit systems like
floating microspheres or microballoons.
EVALUATION OF GRDDS
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Any drug product must be evaluated to ensure its performance characteristics
and to control batch-to-batch quality. In addition to routine tests for general
appearance, hardness, friability, drug content, weight variation, uniformity of
content, disintegration time, and drug release, the gastro retentive performance of
GRDDS must be evaluated.
FLOATING SYSTEMS
Floating/buoyancy time: The test for buoyancy is usually determined in 900 mL of
simulated gastric (HCl/NaCl with 0.02% Tween 80, pH 1.2) or intestinal fluids
KH2PO4/NaOH buffer with 0.02% Tween 80, pH 7.4) maintained at 370C using the
USP dissolution apparatus. These fluids simulate the surface tension of human
gastric juice (35–50 mN/m2). The amount of time the dosage form floats is termed
the floating time. In the case of floating microparticles, the number of floating
particles and the time during which they remain buoyant on the test solution can be
determined. The floating process depends on the balance between the weight and
volume of the dosage form. An increase in the buoyancy force caused by the
increased volume causes a resultant weight increase and leads to dosage-form
flotation.
Specific gravity: The specific gravity of floating systems can be determined by the
displacement method, using benzene as a displacing medium.
BIO/MUCOADHESION SYSTEMS
Bioadhesive strength: The bioadhesive strength of a polymer can be determined by
measuring the force required to separate the polymer specimen sandwiched between
the layers of either an artificial (e.g., cellophane) or biological (e.g., rabbit stomach
tissue) membrane. This force can be measured by using a modified precision balance
or an automated texture analyzer.
SWELLING SYSTEMS
Weight gain and water uptake (WU): The swelling behaviour of a dosage unit can
be measured by studying its weight gain or WU. The study is done by immersing the
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dosage form in simulated gastric fluid at 370C and determining these factors at
regular intervals. The dimensional changes can be measured in terms of the increase
in tablet diameter and/or thickness over time. WU is measured in terms of percent
weight gain, as given by the following equation
WU = (Wt _ W0) × 100/W0
In which,
Wt and W0 are the weights of the dosage form at time t and initially, respectively
Furthermore, the GRDDS should be evaluated for gastro retention and drug-release
behaviour.
METHODS TO ASSESS IN VIVO GASTRORETENTION OF GRDDS
Unlike other formulations, the kinetics of transit of the GRDF along the GI
tract, and especially in determining its GRT are very important. It requires, in most
cases, an imaging technique that can locate the GRDF in vivo. The following
methods have been utilized so far to assess gastroretentivity.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a noninvasive technique that is not
associated with radioactivity and allows observation of the total anatomical structure
in relatively high resolution. The visualization of the GI tract by MRI has to be
further improved by the administration of contrast media. For solid DFs, the
incorporation of a super paramagnetic compound such as ferrous oxide enables their
visualization by MRI. The technique is safe and allows obtaining many pictures from
the same subject.
Radiology (X-ray)
In this technique, a radio-opaque material has to be incorporated in the DF, and
its location is tracked by X-ray pictures. The technique is used to evaluate
gastroretentivity of GRDFs and the disintegration rate of DFs in vivo, and also to
determine the esophageal transit. Although it is considered cheap and a simple
method to use, its major disadvantage is the safety issue owing to repeated exposure
to X-ray that increase the risk for the volunteers.
γ- Scintigraphy
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Gamma scintigraphy relies on the administration of a DF containing a small
amount of radioisotope, e.g., 152Sm, which is a gamma ray emitter with a relatively
short half-life. The isotope has to be incorporated into the GRDF in advance. Then, a
short time prior to the study, the formulation has to be irradiated in a neutron source
that causes it to emit g rays. The emitted ray can be imaged using a ‘‘gamma
camera’’-a form of a scintillation counter, combined with a computer to process the
image, and thereby the DF can be tracked in the GI tract. This technique is elegant
and provides proper assessment of gastroretentivity in humans.
Gastroscopy
Gastroscopy is commonly used for the diagnosis and monitoring of the GI tract.
This technique utilizes a fiber optic or video system and can be easily applied for
monitoring and locating GRDFs in the stomach. However, it is too inconvenient to
conduct the procedure frequently in the same experiment for one subject. In human,
the procedure can be applied with or without slight anesthesia while it requires
complete anesthesia in dogs.
HYPERTENSION
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Figure 9:  hypertension
 Normal blood pressure less than 120/80
 Pre-hypertension 120-139/ 80-89
 High blood pressure (stage 1) 140-159/90-99
 High blood pressure (stage 2) higher than 160/100
Antihypertensive Drugs
Most antihypertensive drugs can effectively reduce mildly elevated blood pressure,
but their use is associated with many side effects. Thus the decision whether to use a
drug to control borderline or mild hypertension is made on the basis of the benefit:
risk ratio.
Antihypertensive Drugs Classification
Drugs influence arterial blood pressure at four effector sites- arterioles (resistance
vessels); veins (capacitance vessels); heart; and the kidneys—by several different
Chapter 1 INTRODUCTION
Dept of Pharmaceutics 33 J.K.K. Nattraja College of Pharmacy
mechanisms. They can be classified according to their site or mode of action as
follows:
Diuretics
(i) Thiazides and related agents (hydrochlorothiazide, chlorthalidone etc.)
(ii) Loop diuretics (frusemide, bumetanide, ethacrynic acid)
(iii) Potassium-sparing diuretics (spironolactone, triamterene, amiloride)
II Sympatholytic Drugs
(i) Centrally acting agents (methyldopa, clonidine).
(ii) Ganglion blocking agents (trimethaphan).
(iii) Adrenergic neuron blocking agents (guanethidine, guanadrel, reserpine).
(iv) Beta-adrenoceptor blockers (metoprolol, atenolol etc.)
(v) Alpha-adrenoceptor blockers (prazosin, terazosin, doxazosin,
phenoxybenzamine).
(vi) Alpha+beta blockers (labetalol, carvediol).
III. Vasodilators
(i) Arterial (hydralazine, minoxidil, diazoxide)
(ii) Arterial and venous (nitroprusside)
IV. Calcium Channel Blockers
Verapamil, nifedipine, nicardipine, nitrendipine.
V.Angiotensin Converting Enzyme Inhibitors
Captopril, enalparil.
VI. Angiotensin II Receptor Blockers
Losartan, valsartan
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Antihypertensive Angiotensin II Receptor Blockers
The older agent, saralasin is an Angiotensin II analogue, and a competitive inhibitor
of Angiotensin II at both its receptors (AT1 and AT2 sites). It blocks the pressor and
aldosterone releasing effects of Angiotensin II, and lowers BP in high rennin states
like renal artery stenosis and ischemia.
Losartan
Losartan is a recently introduced blocker of the AT1 receptor. It has no effect on
bradykinin metabolism, and therefore a moré selective blocker of Angiotensin
effects than the ACE inhibitors.
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Panagiotis et al., (2011) investigated the use of nimodipine–polyethylene glycol
solid dispersions for the development of effervescent controlled release floating
tablet formulations. Nimodipine were optimized in relation to drug release (%
release at 60 min, and time at which the 90% of the drug was dissolved) and floating
properties (tablet’s floating strength and duration), employing a 25-run D-optimal
mixture design combined with artificial neural networks (ANNs) and genetic
programming (GP).
Ray et al., (2010) was developed an optimal gastro retentive drug delivery system
(GRDDS) for administering Losartan. Additionally, the influence of optimized
GRDDS on the bioavailability of Losartan and the formation extent of active
metabolite E3174 by CYP2C9 polymorphism was investigated. Swellable and
floatable GRDDS tablets combining hydroxyethyl cellulose (HEC), sodium
carboxymethyl cellulose (NaCMC), and sodium bicarbonate were prepared at
various compression pressures for evaluating swelling characteristics and floating
capacity.
Londhe et al., (2010) was developed Verapamil hydrochloride bi-layer floating
tablets have two layers one immediate release layer and second floating sustained
release layer. Verapamil hydrochloride bi-layer floating tablet releases drug in two
phases i.e. immediate and sustained drug release. Direct compression method was
used to formulate bi-layer floating tablets. All bi-layer formulation float more than
12 h and sustained drug release above 12 h.
Libo et al., (2009) designed to assess the safety, tolerability and pharmacokinetics
of phenoprolamine hydrochloride floating sustained tablets (PHFST) in healthy
Chinese subjects. Safety and tolerability were appraised by monitoring adverse
events and laboratory parameters. Pharmacokinetics was assessed by determining the
plasma concentrations of phenoprolamine hydrochloride with a validated HPLC
method.
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Mina et al., (2009) was developed a gastro retentive controlled release drug delivery
system with swelling, floating, and adhesive properties. Ten tablet formulations were
designed using hydroxypropylmethylcellulose (HPMC K15M) and/or sodium
alginate (Na alginate) as release-retarding polymer(s) and sodium bicarbonate
(NaHCO3) or calcium carbonate (CaCO3) as a gas former. Swelling ability, floating
behavior, adhesion period and drug release studies were conducted in 0.1 N HCl (pH
1.2) at 37 ± 0.5 C. The tablets showed acceptable physicochemical properties.
Anand et al.,(2009) novel gastro retentive controlled release drug delivery system
of verapamil HCL was formulated in an effort to increase the gastric retention time
of the dosage form and to control drug release. Buoyancy was achieved by adding an
effervescent mixture of sodium bicarbonate and anhydrous citric acid. In vitro drug
release studies were performed, and drug release kinetics was evaluated using the
linear regression method.
Chen et al., (2010) Investigated the effect on compression pressure using
appropriate ratio of Hydroxy ethyl cellulose to sodium carboxymethyl cellulose
(NaCMC), and sodium bicarbonate on losoratan tablets. He concluded that
compression at low pressure resulted in tablet floating over SGF for more than 16 h
and swelling to 2 cm in diameter within 3 h.
Anil et al., (2009) prepared floating delivery system of Ciprofloxacin Hydrochloride
using combination of polymers like Hydroxypropyl methylcellulose (HPMC),
crospovidone, sodium starch glycolate and croscarmelose sodium. He concluded that
combination of HPMC K100M, crospovidone, sodium bicarbonate showed good
swelling, drug release, and floating characters.
Srisagul et al., (2008) Floating multi-layer coated tablets were designed based on
gas formation. The system consists of a drug-containing core tablet coated with a
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protective layer (hydroxypropyl methylcellulose), a gas forming layer (sodium
bicarbonate) and a gas-entrapped membrane, respectively. The obtained tablets
enabled to float due to the  CO2 gas formation and the gas entrapment by polymeric
membrane. The increased amount of a gas forming agent did not affect time to float
but increased the drug release from the floating tablets while increasing coating level
of gas-entrapped membrane increased time to float and slightly retarded drug release.
Strubing et al., (2008a) investigated the mechanism of floating and drug release
behavior of poly(vinyl acetate)-based floating tablets with membrane controlled drug
delivery. MRI studies of selected samples were performed and the results suggested
that the drug release was delayed efficiently within a time interval of 24 h by
showing linear drug release characteristics.
Patel et al., (2007a) used hydroxypropyl methylcellulose, ethyl cellulose, and
sodium bicarbonate to prepare floating tablets and optimization was done using a
simplex lattice design. All the tablet formulations remained buoyant for more than 12
h and the release profile of the optimized batch fitted best to the zero order model.
Bomma et al., (2009) developed floating matrix tablets of norfloxacin to prolong
gastric residence time, leading to an increase in drug bioavailability. Tablets were
prepared by the wet granulation technique, using polymers such as hydroxypropyl
methylcellulose (HPMC K4M, HPMC K100M) and xanthan gum. Non-Fickian
diffusion was confirmed as the drug release mechanism from these tablets, indicating
that water diffusion and polymer rearrangement played an essential role in drug
release.
Lingam et al., (2008) Developed floating multiple mini tablets of Ranitidine HCL
based on gas formation technique. The system consists of loading dose as uncoated
core units, and prolonged-release core units are prepared by direct compression
process; the latter were coated with three successive layers, one of which is seal coat,
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an effervescent (sodium bicarbonate) layer, and an outer polymeric layer of
polymethacrylates. He concluded rapid floating and controlled release properties
were achieved.
Patole et al., (2006) developed floating pulsatile drug delivery system for sequential
release of aceclofenac. A combination of floating and pulsatile principles of drug
delivery system would have the advantage that a drug can be released in distal small
intestine after a defined time period of no drug release. The spherical matrix pellets
of drug and pH-dependent polymer Eudragit S-100 were prepared by extrusion
spheronization process followed by layering with effervescent component (sodium
bicarbonate) using HPMC K100M. The ratios of sodium bicarbonate to HPMC
K100M were 2:8, 5:5 and 8:2 w/w. The pellets are layered with an effervescent agent
to achieve a weight gain of 10, 30, 50 and 70%. Developed formulations showed
instantaneous floating with sequential release of aceclofenac having initial lag time
during floating in acidic medium followed by rapid release in basic medium.
Whitehead et al., (2000) prepared floating alginate beads from alginate solution
contain either dissolved or suspended amoxicillin. Drug release studies showed that
beads prepared with the drug in solution provides some sustained release
characteristics and it could be improved by the addition of amylase. The beads
retained their buoyancy when amylase and amoxicillin were incorporated, exhibiting
resultant weight values greater than zero after 20h.
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AIM AND OBJECTIVE
AIM
The main aim of the study was to formulate Losartan potassium floating tablets and
evaluation of the tablet. One of the most feasible approaches for achieving a
prolonged and predictable drug delivery profile in the GI tract is to control the
gastric residence time (GRT). Dosage forms with a prolonged GRT, i.e. gastro
retentive dosage forms (GRDFs), will provide us with new and important
therapeutic options.
OBJECTIVE
Losartan is antagonist of angiotensin type I receptor leading to
antihypertensive activity by blocking the effects of angiotensin II which include
vasoconstriction and aldosterone-secretion effects. Losartan is slightly soluble in
water which is having half life of 2 hrs and the bioavailability of Losartan is 33% .
To increase the bioavailability of Losartan it would be beneficial to develop a
floating drug delivery system that delays the first pass metabolism prolongs gastric
residence time and releases drug in GI tract, where absorption of Losartan is more
confined. The objective of this research work is to obtain better delivery of Losartan
to the stomach and the proximal parts of the small intestine by increasing the mean
residence time (MRT) in the stomach. For this, floating tablets are prepared to
prolong the gastric emptying that provides maximum drug at the site of absorption.
 The present work is aimed at preparing gastric retentive floating matrix
tablet formulations of Losartan using various polymers. The composition of
these formulations will be selected by using trial and error methods.
 To study the effect of various factors like drug polymer ratio and polymer
grade on the parameters like duration of buoyancy and release rate.
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PLAN OF WORK
The present study was proposed to carry out in the following phases for formulation
and evaluation of sustained release floating matrix tablets of Losartan potassium.
Phase-I:
1. Pre-formulation study of pure drug
2. Compatibility study
Fourier transform infrared spectroscopy (FT-IR)
3. Preparation of standard curve of Losartan potassium
In pH 1.2, 0.1N HCL buffer
Phase-II:
Formulation and evaluation of sustained release floating matrix tablets of Losartan
potassium
1. Formulation of Losartan potassium floating matrix tablets by direct
compression method.
2. Evaluation of Losartan potassium floating matrix tablets
A. Physical evaluation.
B. Drug content study.
C. Swelling study.
D. Buoyancy study.
E. Dissolution study.
F. Kinetic study.
Phase-III:
Stability study of the optimized formulation.
The above given plan of work was presented as flow chart in next upcoming page.
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Flow chart of plan of work
Preformulation studies
Raw material Evaluation
Mixing of powder blend
Evaluation of powder
blend for pre-
compression characters
Compression of Tablets
Evaluation of tablets In vitro studies Buoyancy Determination
Selection of best Formulation
Optimization of Tablet
Formula
Kinetics & Stability testing for optimized
formulation
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DRUG PROFILE
Losartan Potassium
Non Proprietary Name : Losartan Potassium
Proprietary name : hyzaar,lacidipine,lortaan
Chemical name :1H-Imidazole-5-methanol,2-butyl-4-chloro-1-
[[2(lH-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-,monopotassiumsalt.
2-Butyl-4-chloro-1-[p-(o-lH-tetrazol-5-ylphenyl) benzyl] imidazole-5-methanol
Empirical formula : C22H22ClKN6O
Molecular weight : 461 g/mol
Structure:
Physicochemical Profile
Description :  losartan is supplied as a crystalline solid.
Solubility : It is soluble in organic solvents such as ethanol,
DMSO, and dimethyl formamide.
Pharmaceutical Profile
Dosage Forms and dose : it is available as 12.5mg,25, 50 and 100 mg
tablets
Pharmacopoeial status : United States Pharmacopoeia
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Analytical Profile
Spectrophotometry       : Spectrophotometric determination of Losartan
potassium in 0.1N HCL with the λ max at 224nm has been reported.
Pharmacokinetic Profile
Oral absorption : It is well absorbed and the systemic bioavailability
of Losartan is approximately 33%
Plasma half life : 1.5-2 hours
Protein binding : 99.7%
Pharmacological Profile
Therapeutical category :     Anti hypertensive
Mechanism of action
Losartan and its longer acting active metabolite (E-3174) interfere with
the binding of Angiotensin II to the Angiotensin II AT1-receptor by,
themselves, binding reversibly to the receptors in vascular smooth muscle and
the adrenal gland. As Angiotensin II is a vasoconstrictor, which also stimulates
the synthesis and release of aldosterone, blockage of its effects results in
decreases in systemic vascular resistance.
Therapeutic/clinical uses
Losartan is used to treat high blood pressure (hypertension) and to
protect the kidneys from damage due to diabetes. It is also used to lower the
risk of strokes in patients with high blood pressure and an enlarged heart.
Lowering high blood pressure helps to prevent strokes, heart attacks, and
kidney problems. Losartan belongs to a class of drugs called Angiotensin
receptor blockers. It works by relaxing blood vessels so that blood can flow
more easily.
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Adverse effects :
Adverse effects of losartan have been reported to be usually mild and
transient, and include dizziness, headache, and dose-related orthostatic
hypotension. Hypotension may occur particularly in patients with volume
depletion (for example those who have received high-dose diuretics). Impaired
renal function and rarely rash, urticaria, pruritus, angioedema, and raised liver
enzyme values may occur. Hyperkalaemia, myalgia, and arthralgia .
Contraindications:
Losartan should not be administered to pregnant women and breast-
feeding mothers, because it may disturb the fetal growth or may be harmful to
the newborn. It should be cautiously used in patients with renal failure or liver
disfunction.
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POLYMER PROFILE
HYDROXY PROPYL METHYL CELLULOSE (HPMC)
Synonyms: Methocel, hypromellose.
According to the European pharmacopoeia hydroxypropyl methyl
cellulose (hypromellose) is partly o-methylated and o-(2-hydroxypropylated)
cellulose.
R: -H, -CH3 or -CH2CH (CH3) OH.
Hypromellose is an inert, odourless, tasteless, non-ionic, hydrophilic
polymer. It is prepared from purified cellulose, which is obtained from cotton
linters or wood pulp.
Physicochemical properties of hypromellose:
Solubility, glass transition temperature and viscosity depend upon the
ratio of methoxy and hydroxypropoxy groups and the molecular weight. The
molecular weight of hypromellose ranges from 10000 to 1500000. Various
grades of hypromellose are available which differ in viscosity and extent of
substitution. The different grades may be identified by a number indicative of
apparent viscosity, in mPa.s, of a 2% aqueous solution at 20°C.The USP
identifies hypromellose polymers into four different types according to their
relative methoxy-group and hydroxypropoxy-group contents. These are HPMC
1828, HPMC 2208, HPMC 2906, and HPMC 2910. The first two numbers
represent the percentage of methoxy groups, the last two numbers the
percentage of hydroxypropoxy groups, determined after drying at 105°C for
2hr.
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Solubility:
It is practically insoluble in hot water, in absolute ethanol, in acetone, in ether,
and in toluene. It dissolves in cold water forming a colloidal solution.
Gel point   : 500C to 900C
pH : 6.0 to 8.0 (1% aqueous solution)
Stability : Very stable in dry conditions, solutions are stable at
pH3.0-11.0. Aqueous solutions are liable to be effected by
microbes.
Applications:
 Suspending agent, viscosity modifier, film and matrix forming material.
 Tablet binder and adhesive ointment ingredient
LACTOSE SPRAY DRIED
Synonyms:
FlowLac 100, Lactopress Spray-Dried, NF Lactose–316 Fast Flo, NF
Lactose–315, Pharmatose DCL 11, Pharmatose DCL 14, Super-Tab Spray-
Dried.
Chemical name:
Spray-dried lactose is a mixture of amorphous lactose, which is a 1 : 1
mixture of α-and-β-lactose, and O-β-D-galactopyranosyl-(14)-α-D-
glucopyranose monohydrate.
Empirical Formula and Molecular Weight:
C12H22O11 : 342.30 (for amorphous)
C12H22O11 H2O  :360.31 (for monohydrate)
Functional Category:
Binding agent, directly compressible tablet excipient, tablet and capsule
diluents, tablet and capsule filler.
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Applications in Pharmaceutical Formulation Technology:
Spray-dried lactose is widely used as a binder, filler-binder, and flow
aid in direct compression tableting.
Description:
Lactose occurs as white to off-white crystalline particles or powder. It is
odourless and slightly sweet-tasting. Spray-dried direct-compression grades of
lactose are generally composed of 80–90% specially prepared pure lactose
monohydrate along with 10–20% of amorphous lactose.
Method of manufacture:
A suspension of lactose monohydrate crystals in a lactose solution is
atomized and dried in a spray drier(2,3) Approximately 10–20% of the total
amount of lactose is in solution and the remaining 80–90% is present in the
crystalline form. The spray-drying process predominantly produces spherical
particles. The compactibility of the material and its flow characteristics are a
function of the primary particle size of the lactose monohydrate and the amount
of amorphous lactose.
Safety:
Lactose is widely used in pharmaceutical formulations as a diluent in
oral capsule and tablet formulations. It may also be used in intravenous
injections. Adverse reactions to lactose are largely due to lactose in tolerance,
which occurs in individuals with a deficiency of the enzyme lactase.
Handling Precautions:
Observe normal precautions appropriate to the circumstances and
quantity of material being handled. Excessive generation of dust, or inhalation
of dust, should be avoided.
Stability and Storage Conditions
Spray-dried lactose should be stored in a well-closed container in a cool,
dry place.
Chapter 5 DRUG PROFILE
Dept of Pharmaceutics 48 J.K.K.Nattraja College of Pharmacy
SODIUM BICARBONATE
Synonyms         : Sodium hydrogen carbonate, Baking soda, Effer-Soda.
Chemical name: Carbonic acid monosodium salt.
Empirical formula: NaHCO3
Description       : Occurs as an odorless, white crystalline powder with a
saline taste. The crystalline structure is monoclinic
prisms.
Solubility           : Soluble in water, practically insoluble in ethanol and
ether.
Melting point     : 2700C
Stability and Storage: when heated to about 500C, sodium bicarbonate begins
to dissociate into carbon dioxide, sodium carbonate and water. On heating to
250-3000C for a short time, sodium bicarbonate is completely converted into
anhydrous sodium carbonate.
Application in pharmaceutical technology
 Sodium bicarbonate is generally used in pharmaceutical formulations as
a source of carbon dioxide in effervescent tablets and granules in
combination with either citric or tartaric acid.
 Buffering agent.
 Therapeutically it is used as an antacid and as a source of the
bicarbonate anion in the treatment of metabolic acidosis.
 It is also used as a component of oral rehydration salts. It is used in food
products as leavening agent.
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MAGNESIUM STEARATE
Synonyms : Magnesium octadecanoate, octadecanoic acid,
magnesium salt.
Chemical name     : Octadecanoic acid magnesium salt.
Empirical formula: C36H70MgO4
Description:
Magnesium Stearate is a very fine, light white, precipitated or milled,
impalpable powder of low bulk density, having a faint odour of stearic acid and
a characteristic taste. The powder is greasy to the touch and readily adheres to
the skin.
Solubility:
It is practically insoluble in ethanol, ethanol (95%), ether and water;
slightly soluble in warm benzene and warm ethanol (95%).
Melting point:
117-1500C (commercial samples);
126-1300C (high purity magnesium stearate)
Functional category: Tablet and capsule lubricant.
Applications in pharmaceutical formulation or technology:
 Primarily used as a lubricant in capsule and tablet manufacture at
concentrations between 0.25% and 5.0% w/w.
 It is widely used in cosmetics, foods, and pharmaceutical formulations.
 It is also used in barrier creams.
TALC
Synonyms:
Altalc, hydrous magnesium calcium silicate, hydrous magnesium
silicate, purified French chalk, soapstone, steatite, Magsil Star, superior.
Chemical name     : Talc
empirical formula: Mg6 (Si2O5)4(OH)4
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Description:
Talc is a very fine, white to greyish-white, odourless, impalpable,
unctuous, crystalline powder. It adheres readily to the skin and is soft to the
touch and free from grittiness.
Solubility:
Practically insoluble in dilute acids and alkalis, organic solvents, and
water.
Stability and Storage conditions:
Talc is a stable material and may be sterilized by heating at 1600C for
not less than 1 hour. It may also be sterilized by exposure to ethylene oxide or
gamma irradiation. Talc should be stored in a well-closed container in a cool,
dry place.
Functional Category   :
Anti caking agent; glidant; tablet and capsule diluents; tablet and
capsule lubricant.
Applications :
 Talc is also used as a lubricant in tablet formulations; in a novel powder
coating for extended-release pellets; and as an adsorbent.
 Talc is additionally used to clarify liquids and is also used in cosmetics
and food products, mainly for its lubricant properties.
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6. METERIALS AND METHODS
List of materials and instruments was described in table no 5 and 6
Table 5: LIST OF MATERIALS
S. No MATERIAL SUPPLIED BY
1 Losartan Aurobindo Pharma Limited
2 HPMC K4M Aurobindo Pharma limited
3 HPMC K15M Aurobindo Pharma limited
4 HPMCK100M Aurobindo Pharma limited
5 Lactose Zeal  Chemicals (P) Ltd. Warangal .
6 Talc Taurus Chemicals (P) Ltd. Secunderabad.
7 Magnesium Stearate Taurus Chemicals (P) Ltd. Secunderabad.
8 Sodium bicarbonate Zeal  Chemicals (P) Ltd. Warangal.
Table 6: LIST OF INSTRUMENTS
S. No INSTRUMENTS MANUFACTURER
1 Electronic balance Shimadzu ELB-300
2 Sieve no 40 Jaico metals
3 Tablet compression machine Kimya engineers
4 Tablet hardness tester Monsanto
5 Friability test apparatus Roche Friabilator
6 Tablet dissolution tester Lab India
7 Bulk density apparatus Keetan&company
8 Stability control oven Biotechno lab, BTL
9 UV-Visible spectrophotometer Lab India, Lambda 25
10 FTIR spectrophotometer Bruker Alpha-T
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6.1 PRE-FORMULATION STUDIES:
Preformulation may be described as a phase of the research and development
process where the formulation scientist characterizes the physical, chemical and
mechanical properties of new drug substances, in order to develop stable, safe and
effective dosage forms. Ideally the preformulation phase begins early in the
discovery process such the appropriate physical, chemical data is available to aid the
selection of new chemical entities that enter the development processed during this
evaluation possible interaction with various inert ingredients intended for use in
final dosage form were also considered in the present study.
The following pre-formulation studies were performed:
 Study of organoleptic properties
 Solubility analysis
 Melting point of drug
 Drug powder characterization
 Physical compatibility studies
 Identification of drug-excipients compatibility study by FT-IR
6.1.1 Organoleptic properties:
The Organoleptic character of the drug like colour, odour, taste and appearance play
an important role in the identification of the sample and hence they should be
recorded in an descriptive terminology.
6.1.2 Solubility Studies
It is important to know about solubility characteristics of a drug in aqueous systems,
since they must posses some limited aqueous solubility to elicit a therapeutic
response. Quantitative determination of solubility was made by preparing saturated
solution of drug in a constant volume of pH 1.2, 6.8, 7.4 phosphate buffers and
resulting solutions were kept at room temperature for 24 hours with intermediate
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shaking. The resulting solutions were filtered and analyzed for dissolved drug by
U.V spectrophotometry at λmax of 224 nm.
6.1.3 Melting point:
The melting point of Losartan potassium was determined by capillary method,
using small quantity of Losartan potassium is taken and placed in apparatus and
determined the melting point and matched with standards.
6.1.4 Loss on drying:
Determined 1.000 g by drying in an oven at 100°C to 105°C for 3 hours.
Accurately weighed the substance to be tested.  If the sample was in the form of
large crystals, reduce the particle size to about 2 mm by quickly crushing.  Tare a
glass stopper, shallow weighing bottle that has been dried for 30 minutes under the
same conditions to be employed in the determination.  Put the sample in bottle,
replace the cover and accurately weighed the bottle and the contents.  By gentle,
sidewise shaking, distribute the sample as evenly as practicable to a depth of about 5
mm.  Place the loaded bottle in the drying chamber.  Dried the sample at the
specified temperature from constant weight. Upon opening the chamber, close the
bottle promptly and allow it to come to room temperature in desiccators before
weighing.
The difference between successive weights should not be more than 0.5mg.
The loss on drying is calculated by the formula:
(W2-W3)
% LOD = ----------------------------- X 100
(W2-W1)
Where,      W1 = Weight of empty weighing bottle
W2 = Weight of weighing bottle + sample
W3 = Weight of weighing bottle + dried sample
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6.1.5 Drug powder characterization:
6.1.5.1 Angle of repose: Angle of repose is the maximum angle of a stable slope
determined by friction, cohesion and the shapes of the particles. The internal angle
between the surface of the pile and horizontal surface is known as the angle of
repose and is related to the density, surface area and co-efficient of friction of the
raw material.
Method: Angle of repose was determined by using funnel method. The height of the
funnel was adjusted in such a way that the tip of the funnel just touches the heap of
the blends. Accurately weighed blend was allowed to pass through the funnel freely
on the surface. The height and diameter of the powder cone was measured and angle
of repose was calculated using the following equation.
Ө = tan-1 (h/r)
Where, h = height of heap, r = radius of heap, Ө = angle of repose.
Table 7: Limits:
Angle of repose Flow property
<25o Excellent
25-30 o Good
30-40 o Passable
>40 o Very poor
6.1.5.2 Bulk density: Bulk density is defined as the mass of the powder divided by
the bulk volume. Bulk density largely depends on particle shape, as the particle
become more spherical in shape, bulk density is increased. In addition as the granule
size increases bulk density decreases.
Method: weighed quantity of active powder ingredient (API) was transferred into
100 ml measuring cylinder without tapping during transfer. The volume occupied by
the API was measured. Bulk density was measured by using the formula
Bulk Density = Bulk Mass / Bulk Volume
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6.1.5.3 Tapped density: Tapped density is achieved by mechanically tapping a
measuring cylinder containing a powder sample. After observing the initial volume,
the cylinder is mechanically tapped and volume readings are taken until little further
volume changes is observed the mechanical tapping is achieved by raising the
cylinder and allowing it to drop under its own weigh a specific distance. Device that
rotates device during tapping may be preferred to minimize any possible separation
of the mass during tapping down.
Cylinder dropping distance: 14± 2mm at a normal rate of 300 drops / minute.
Unless otherwise specified, tab the cylinder 500 times initially and measure the
tapped volume Va, the nearest graduated unit. Repeat the tapping an additional 750
times and measure the tapped volume, Vb, to the nearest graduated unit. If the
difference between the two volumes is less than 2%, Vb is the final tapped volume,
Vf . Repeat in increments of 1250 taps, as needed, unit the difference between
succeeding measurements is less than 2%. Calculate the tapped density, in gm per
ml, by the formula:
Tapped Density =
Vf
m
Where, m = initial weight of material in gm,
Vf = volume of material after tapping.
Generally replicate determinations are desirable for the determination of this
property.
6.1.5.4 Measurement of Powder Compressibility:
The compressibility Index and Hausner’s ratio are measures of the
propensity of a powder to be compressed. As such, they are measures of the relative
importance of inter particulate interactions. In a free flowing powder, such
interactions are generally less and tapped densities will be closer in value. For
poorer flowing materials, there are frequently greater inter particle interactions, and
a greater difference between bulk and tapped densities will be observed. These
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differences are reflected in the compressibility Index and the Haussler ratio which
was  calculated by the following formula:
Compressibility index: =
0
0 )(100
V
VfV 
Where, Vf = final tapped volume, Vo = initial un tapped volume.
Table 8: Limits
S.no Compressibility index Flow
1 5-12 Free flow
2 12-16 Good flow
3 18-21 Fair
4 23-25 Poor
5 33-38 Verypoor
6 >40 Extremelypoor
Hausner’s ratio: =
Vf
V0
Where, Vf = final tapped volume, Vo = initial un tapped volume.
Table 9: Limits
S.No Hausner’s ratio Flow
1 1-1.2 Free flowing
2 1.2-1.6 Cohesive powder
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6.1.5.5 Physical compatibility studies:
In the tablet dosage form the drug is in intimate contact with one or more
excipients, the latter could affect the stability of the drug. Knowledge of drug
excipient interactions, therefore very useful to the formulator in selecting the
appropriate excipients.
Losartan potassium was mixed well with the excipients according to the formula
selected for the tabletting and kept small portion of this mixed powder in cleaned
and dried vials in stability chamber at 40oC±2o C / 75±5RH and room temperature.
Physical observations have been carried out visually for 7 days
6.2 Drug-Excipient Compatability Studies
6.2.1 Fourier Transform Infrared (FTIR) Spectroscopy
The Infrared spectra of samples were obtained using by infrared
spectrophotometer. Pure drug, excipients, physical mixture of drug and
excipients  were subjected to FTIR study. The IR spectra were obtained using
KBr disk method
6.3 Construction of calibration curve
6.3.1 Standard graph of Losartan potassium in 0.1N HCl
The stock solutions were freshly prepared by dissolving 100mg of
Losartan in a 100ml volumetric flask and then made up the solution up to the
mark using 0.1N HCl for obtaining the solution of strength 1000 µg/ml (stock
I). 10ml of this solution was diluted to 100ml with 0.1N HCl to obtain a
solution of strength 100 µg/ml (stock II). From this secondary stock required
concentrations 2, 4, 6, 8, 10, 12 and 14 µg/ml is prepared. The absorbance was
measured at 224 nm using a UV Spectrophotometer.
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6.4 Formulation of floating matrix tablets of Losartan potassium:
The key ingredients included in the formulation are:
Hydrophilic polymers: HPMC K4M, HPMC K15M, and HPMC K100M
Effervescent agent     : Sodium carbonate
Filler : Lactose
Anti adherent : Talc
Lubricant : Magnesium Stearate
Accurately weighed quantities of polymer and lactose were taken in a
mortar and mixed geometrically to this required quantity of Losartan was added
and mixed with the pestle. Accurately weighed quantity of sodium bicarbonate
was then mixed with the drug blend. The powder blend was then lubricated
with magnesium stearate and talc mixed for about 3 minutes. Finally this
mixture was compressed on a 16-station rotary tablet machine using 10-mm
standard flat-face punches.
Chapter 6 METHODOLOGY
Dept of Pharmaceutics 59 J.K.K.Nattraja College of Pharmacy
Table10: Composition of floating matrix tablets of Losartan potassium
Ingredient
(mg)
Composition(mg)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Losartan
potassium
50 50 50 50 50 50 50 50 50 50 50 50
HPMC
K4M 75 100 125 - - - - - - 50 - 50
HPMC
K15M - - - 75 100 125 - - - 50 50 -
HPMC
K100M - - - - - - 75 100 125 - 50 50
NaHCO3 50 50 50 50 50 50 50 50 50 50 50 50
Lactose 172 147 122 172 147 122 172 147 122 147 147 147
Mg.
Stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Total
wt
( mg)
300 300 300 300 300 300 300 300 300 300 300 300
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6.5 Evaluation of floating matrix tablets of Losartan potassium
6.5.1 Tablet thickness and Diameter
Thickness and diameter of tablets were important for uniformity of tablet size.
Thickness and diameter were measured using vernier callipers.
6.5.2 Hardness
This test is used to check the hardness of a tablet which may undergo chipping
or breakage during storage, transportation and handling. In this six tablets were
selected at random and the hardness of each tablet was measured with
Monsanto hardness tester. The hardness is usually measured in terms of kg/cm2.
6.5.3 Friability
The friability test was carried out to evaluate the hardness and stability instantly
in Roche Friabilator. Here twenty tablets were weighed (Wo) initially and put
in a tumbling and rotating apparatus drum. Then, they are subjected to fall from
6 inches height. After completion of 100 rotations i.e., 25 rpm for 4 minutes,
the tablets were again weighed (w). The percent loss in weight or friability (F)
is calculated by the formula
F= (1-W/Wo) x 100
F= friability
Wo= initial weight
6.5.4 Weight variation
This test was performed to maintain the uniformity of weight of each tablet
which should be in the prescribed range. This was done by sampling randomly
and weighing 20 tablets and average weight is calculated. Not more than two of
the individual weights deviate from the average weight by more than the
percentage show in the table 11 and none deviate by more than twice the
percentage. The mean and standard deviation were determined.
Chapter 6 METHODOLOGY
Dept of Pharmaceutics 61 J.K.K.Nattraja College of Pharmacy
Table 11:  Pharmacopoeial specifications for tablet weight variation
Average
weight of
tablets (mg)
(I.P)
Average weight
of tablets   (mg)
(U.S.P)
± %
deviation
allowed
Less than 80 Less than 130 10
80 – 250 130 – 323 7.5
More than 250 More than 324 5
6.5.5 Content Uniformity
This test was performed to maintain the uniformity of weight of active
ingredient in each tablet which should be in the prescribed range according to
the Indian Pharmacopoeia. This test was performed by taking twenty tablets
randomly, weighed and powdered. A quantity of powdered tablet equal to 100
mg of losartan is dissolved in 0.1 N HCL in 100ml volumetric flask. It is
diluted and the absorbance is measured at 224 nm using 0.1 N HCL as blank
and the % drug content was estimated using the following formula.
Absorbance-intercept
Concentration (mcg/ ml) = -------------------------------
Slope
Drug content (mg) = concentration x dilution factor
Drug content (mg)
% Drug content = -------------------------- x 100
Label claim (mg)
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6.6 In vitro buoyancy determination
The floating characteristics of the GFDDS are essential, since they influence the
in vivo behaviours of the drug delivery system. However there seemed to be no
threshold value for the floating system to remain a float under a physiological
condition due to the latter's complication.
6.6.1 Floating Lag Time: The time taken by the tablet to emerge onto the
surface of the liquid after adding to the dissolution medium at pH 1.2,
temperature 37 ± 0.5˚C, paddle rotation at 50 rpm.
6.6.2 Total Floating Time: The time taken by the tablet to float constantly on
the surface of the  gastric fluid , at pH 1.2, temperature 37 ± 0.5˚C, paddle
rotation at 50 rpm.
6.6.3 Buoyancy / Floating Test:
The in vitro buoyancy was determined by floating lag time, as per the method
described by a Rosa et al.,1994. Here, the tablets were placed in a 100-mL beaker
containing 0.1N HCl. The time required for the tablet to rise to the surface and float
was determined as floating lag time and total duration of time by which dosage form
remain buoyant is called Total Floating Time (TFT).
6.6.4 Water uptake studies:
The swelling behaviour of dosage unit can be measured either by studying its
dimensional changes, weight gain or water uptake. The water uptake study of the
dosage form was conducted by using USP dissolution apparatus-II in a 900ml of
distilled water which was maintained at 37o+ 0.5oc, rotated at 50 rpm. At selected
regular intervals the tablet is withdrawn and weighed. Percentage swelling of the
tablet was expressed as percentage water uptake (%WU)(Chavanpatil et al., 2006).
%WU   = (Wt - Wo) * 100 / Wo
Where Wt is the weight of the swollen tablet and   Wo is the initial weight of the
tablet.
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6.7 In vitro dissolution studies
Dissolution studies were carried out using USP II dissolution apparatus. The
stirring speed was 50 rpm. 0.1 N hydrochloric acid is used as dissolution
medium (900ml). It was maintained at 37 ± 1˚C. Samples of 5ml were
withdrawn at predetermined time intervals, filtered and replaced with 5ml of
fresh dissolution medium. The collected samples were suitably diluted with
dissolution fluid wherever necessary and were analyzed  at 224 nm by using a
double beam UV spectrophotometer. Each dissolution study is performed three
times and the mean values were taken.
6.8 Kinetic model fitting:
To analyze the in vitro release data and to determine the release mechanism
various kinetic models were used. The zero order rate Eq. (1) describes the
systems where the drug release rate is independent of its concentration. The
first order Eq. (2) describes the release from system where release rate is
concentration dependent (Bourne, 2002). Higuchi (1963) described the release
of drugs from insoluble matrix as a square root of time dependent process based
on Fickian diffusion Eq. (3). The Hixson-Crowell cube root law Eq. (4)
describes the release from systems where there is a change in surface area and
diameter of particles or tablets (Hixson and Crowell, 1931).
There are several linear and non-linear kinetic models to describe release
mechanisms (Higuchi, Peppas model) and order of release(Zero and First
order).
 Zero order kinetics
 First order kinetics
 Korsmeyer-Peppas model
 Higuchi model
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6.8.1 Zero order kinetics
Drug dissolution from pharmaceutical dosage forms that do not disaggregate
and release the drug slowly (assuming that area does not change and no
equilibrium conditions are obtained) can be represented by the following
equation
W0 – Wt = K0t
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt
is the amount of drug in the pharmaceutical dosage form at time t and k is
proportionality constant.  Dividing this equation by W0 and simplifying
ft = k0t
Where ft = 1 – (Wt / W0 ) and ft represents the fraction of drug dissolved in time
t and k0 the apparent dissolution rate constant or zero order release constant in
this way, a graphic of the drug-dissolved fraction versus time will be linear if
the previously established conditions were filled. In this way a graphical
relationship between ft versus time to get the Zero order constant from the
slope. This relation can be used to describe the drug dissolution of several types
of modified release pharmaceutical dosage forms, as in the case of some
transdermal systems as well as matrix tablets with low soluble drugs (Varelas et
al., 1995), coated forms, osmotic systems, etc. the pharmaceutical dosage forms
following this profile release the same amount of drug by unit of time and it is
the ideal method of drug release in order to achieve a pharmacological
prolonged action.
6.8.2 First order kinetics
This type of model to analyze drug dissolution study is first proposed by
Gibaldi and Feldman and later by Wagner. The relation expressing this model
Log Qt = Log Q0 + K1t/2.303
Where Qt is the amount of drug released in time t, Q0 is initial amount of drug
in the solution and K1 is the first order release rate constant. In this way a
graphical relationship between log percent drug remaining versus time to get
the first order constant from the slope. The pharmaceutical dosage forms
following this dissolution profile, such as those containing water-soluble drugs
in porous matrices release the drug in a way that is proportional to the amount
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of drug remaining in its interior, in such a way, that the amount of drug released
by unit of time diminishes.
6.8.3 Korsmeyer Peppas model (power law)
Korsmeyer et al., (1983) developed a simple semi empirical model, relating
exponentially the drug release to the elapsed time (t)
Qt/Qα = Kktn
Where Kk is a constant incorporating structural and geometric characteristic of
the drug dosage form and n is the release exponent, indicative of the drug
release mechanism. For matrix tablets, an n value of <0.5 indicates diffusion –
controlled mechanism while an n value of <1.0 indicates erosion (Ford et al.,
1991). Hariharan et al., 1997 a suggested that if the value of n is 0.5, it indicates
Fickian transport, a value of 0.5 and 1.0 non-Fickian transport, and the values
close to 1.0 indicate that the system is releasing drug in a zero-order manner
regardless of the actual mechanism of release.
Table 12: Release Mechanism –Korsmeyer Peppas Kinetic Model
Release exponent
(n)
Drug transport
mechanism
Rate as a function of
time
0.5 Fickian diffusion t-0.5
0.5<n<1.0
Anomalous transport
or   non-Fickian
tn-1
1.0 Case-II transport Zero-order release
Higher than 1.0
Super Case-II
transport
tn-1
This type of analysis of release behaviour is valuable to the formulator for
comparative purposes (Hariharan et al., 1997b). The Release exponent can be
obtained from the slope and the Constant (Kk) obtained from the intercept of the
graphical relation between logarithmic versions of left side of the equation
versus log t. This model is used to analyze the release from polymeric dosage
forms, when the release mechanism is not well known or when there is a
possibility of more than one type of release phenomenon being involved.
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6.8.4 Higuchi Model (Higuchi 1961, Higuchi 1963)
Qt = KHt1/2
Where Qt = the amount of drug released at time t and
KH = the Higuchi release rate;
This is the most widely used model to describe drug release from
pharmaceutical matrices. A linear relationship between the square root of time
versus the concentration indicates that the drug release follows strict Fickian
diffusion. For purpose of data treatment, the above equation is usually reduced
to:
Q = Kt1/2
Therefore a plot of amount of drug released versus the square root of time
should be linear if drug release from the matrix is diffusion controlled.
Alternatively, the drug release rate is proportional to the reciprocal of the
square root of time. An important advantage of the above equations is its
simplicity.
The following plots were made using the in-vitro drug release data:
 Cumulative % drug release vs. time (Zero order kinetic model);
 Log cumulative of % drug remaining vs. time (First order kinetic
model);
 Cumulative % drug release vs. square root of time (Higuchi model);
 Log cumulative % drug release vs. log time (Korsmeyer – Peppas
model).
Chapter 6 METHODOLOGY
Dept of Pharmaceutics 67 J.K.K.Nattraja College of Pharmacy
6.9 Stability protocol:
The purpose of stability testing is to provide evidence on how the quality of a drug
substances or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light and to establish a re-
testing for the drug substances or a shelf-life for the drug product and recommended
storage conditions.
The storage conditions used for stability studies were accelerated conditions
(40°C±2°C/75%±5% RH).Stability study was carried out for the optimized
formulation. Tablets of optimized formulation were striped packed and kept in
stability chamber for 3 months on above mention temperature.
Test Performed:
 Test for other physical parameters.
 Dissolution profile.
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7. RESULTS AND DISCUSSIONS
7.1 PRE-FORMULATION STUDIES
7.1.1 Organoleptic properties
Table 13: Observation of organoleptic properties:
TEST SPECIFICATION OBSERVATION
Colour White or almost white powder White powder
Odour --- Odourless
7.1.2 Solubility analysis
Losartan potassium samples are examined and it was found to be soluble in
water and phosphate buffer pH 1.2, 6.8and 7.4.
7.1.3 Melting point of drug
The melting point of Losartan potassium was determined by capillary
method, melting point of Losartan potassium was found to be 184°C. Melting point
compared with USP standards that showed that drug was pure.
7.1.4 Loss of Drying
It was determined as per procedure given in methodology. The results were
as follows
Table 15: Observations for loss on drying
Test Loss on drying Observation
Loss on drying Not more than 0.5% 0.41%
The loss drying of drug was founded as0.41 which was within the limit.
7.1.5 Drug powder characterization:
7.1.5.1 Angle of repose
It was determined as per procedure given in material and methodology
section.
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Table 14: Determinations of Angle of repose
Material Angle of repose
Losartan potassium Raw
material
24°56"
The results indicating that the raw material has good flow property.
7.1.5.2 Flow properties
The method to determine the flow properties are given in methodology.
Table 16: Flow properties of pure drug
Material Bulk density Tapped
density
Carr’s
index (%)
Hausner’s
ratio (%)
Losartan
potassium
raw material
0.347±0.04 0.391±0.07 15.52±0.01 1.19±0.06
The results are clearly indicating that the Losartan potassium raw material has good
flow and cohesive nature.
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7.2 FTIR Studies
Potential chemical interactions between the drug and polymer may change the
therapeutic efficacy of the drug. To investigate the possibilities of chemical
interaction between drug and excipients. FTIR spectra of pure drug and optimized
formulations were analyzed over the range 400-4000cm-1. (shown in Figure 10 to
15) the IR spectrum of pure Losartan potassium showed strong absorption bands at
wave numbers of 3195, 2957, 1460, 1423, 1260 , 995.8,and763.7cm-1. Due to
hydroxyl stretching--- OH, C—H, C=0 stretching, N-H bending, C-H bend in plane
and C-C stretching respectively in optimized formulations also these peaks were
well preserved with additional peaks which correspond to the excipients used in the
formulation. This indicates no drug-excipient interaction
Figure 10: FTIR spectra of pure drug, Losartan potassium
wave number cm-1
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Figure 11: FTIR spectra of HPMC
Figure 12: FTIR spectra of LACTOSE
wave number cm-
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Figure 13: FTIR spectra of Mg.stearate
wave number(cm-1)
Figure 14: FTIR spectra of Talc
wave number cm-1
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Figure 15 : FTIR spectra of pure drug and polymers
wave number cm-1
\
S. No Functional Group Observed Value
(cm-1)
Theoretical value
(cm-1)
1
C-H stretching 763.05 1000-675
2
O-H stretching 995.29 1050-1150
3
C-N stretching 1260.47 1340-1020
4
C-O stretching 1423.10 1250-1350
5
C=C stretching 1460.23 1450-1600
6
N-H   bending 2957.64 2500-3000
7
C-H   bending 3195.36 3500-4000
Peaks were well preserved with additional peaks which correspond to the excipients
used in the formulation. This indicates no drug-excipient interaction
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7.3 Standard graph of Losartan in 0.1N HCL
The scanning of the volumetric solution of Losartan in the ultraviolet range
(200-400nm) against 0.1 N HCL blank gave the max as 224 nm. The standard
concentrations of Losartan (2-14 µg/ml) prepared in 0.1N HCL showed good
linearity with R2 value of 0.9989, which suggests that it obeys the Beer-Lamberts
law.
Table19: Absorbance of Losartan potassium of different concentrations at
λmax (224nm).
Figure16: Standard graph of Losartan potassium in 0.1N HCL
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7.4 EVALUVATION OF PRECONPRESSION PARAMETERS
The following parameters were carried out by the procedure given in 6.1.5.1.
The results were illustrated in the below table.
Formulation
code
Angle of
repose
(degree± SD)
BD
(gm/ml±
SD)
TD
(gm/ml±
SD)
Carr’s
index
(%± SD)
Hausner’s
ratio
(%± SD)
F1 24.12±0.04 0.317±0.01 0.367±0.02 14.65±0.06 1.08±0.05
F2 23.07±0.01 0.327±0.03 0.389±0.04 15.21±0.07 1.09±0.04
F3 26.04±0.03 0.337±0.06 0.381±0.01 13.63±0.04 1.11±0.02
F4 25.0i±0.07 0.347±0.04 0.391±0.07 16.52±0.01 1.19±0.06
F5 22.97±0.09 0.296±0.03 0.320±0.03 13.12±0.03 1.16±0.03
F6 25.71±0.06 0.260±0.01 0.336±0.01 15.27±0.01 1.15±0.01
F7 24.16±0.03 0.266±0.04 0.372±0.02 14.56±0.04 1.16±0.03
F8 21.11±0.09 0.307±0.05 0.332±0.03 13.41±0.07 1.17±0.05
F9 26.16±0.04 0.312±0.02 0.356±0.01 16.31±0.05 1.18±0.04
F10 26.04±0.03 0.347±0.04 0.381±0.01 13.63±0.04 1.11±0.02
F11 25.0i±0.07 0.296±0.03 0.391±0.07 16.52±0.01 1.19±0.06
F12 22.97±0.09 0.260±0.01 0.320±0.03 13.12±0.03 1.16±0.03
7.4.1 Physical compatibility test
The method for determination of physical compatibility test was given in
methodology.
Table 17: Observation for physical compatibility test
Test Observation Inference
Description No colour change was observed Complies with the condition
The physical compatibility evaluation was performed in visual basis. The study
implies that the drug, polymer and other excipients were physically compatible with
each other as there was no change of physical description.
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7.5 Evaluation of physical parameters of floating matrix tablets of Losartan
potassium
All the prepared formulations were tested for physical parameters like
Hardness, Thickness, Weight variation, Friability, Total floating time, Floating lag
time are fond to be within pharmacopeias limits. The drug content of all the
formulations was determined and was found to be within the permissible limit. This
study indicates that prepared formulations were good.
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Table 20: Physical parameters of floating matrix tablets of Losartan potassium.
All values represent mean ± standard deviation (SD) n=3.
Batch
No
Tablet
Thickness
(mm)
Weight
Variatio
n(mg)
Hardness
Kg/cm2
Drug
content
(%)
Friability
(%)
Lag
time
(sec)
Total
floating
time(sec)
F1 3.52±0.05 350±7.2 4.0±0.4 98.78±1.2 0.44 65 >12
F2 3.53±0.07 350±8.3 4.1±0.3 97.6±0.98 0.45 68 >12
F3 3.55±0.06 352±7.1 4.06±0.6 96.6±0.43 0.36 70 >12
F4 3.53±0.03 352±9.4 4.02±0.4 93.3±1.43 0.51 80 >12
F5 3.51±0.08 351±7.8 4±0.2 86.6±0.56 0.52 73 >12
F6 3.52±0.04 350±9.4 4.3±0.2 99.9±1.43 0.27 70 >12
F7 3.56±0.07 351±8.6 4.0±0.2 98.1±0.97 0.37 52 >12
F8 3.55±0.05 349±11.6 4.3±0.3 101±1.03 0.38 45 >12
F9 3.51±0.05 349±10.5 4.0±0.2 99.3±1.02 0.42 45 >12
F10 3.59±0.05 349±9.2 4.2±0.5 99.3±1.32 0.45 75 >12
F11 3.53±0.08 352±1.4 4.2±0.2 97.37±2.6 0.45 55 >12
F12 3.58±0.05 351±8.6 4.1±0.5 97.5±2.31 0.43 70 >12
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7.6 SWELLING STUDIES:
Table 21: Percent swelling of formulations with HPMC K4M and K15M
All values represent mean ± standard deviation (SD) n=3.
Figure17.Percent swelling of formulations with HPMC K4M&K15M
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Sampling
time(hr) F1 F2 F3 F4 F5 F6
1 15.41 21.83 23.53 16.97 22.87 22.45
2 19.96 34.33 37.65 22.47 35.73 36.42
3 42.19 52.33 56.63 48.34 53.68 54.66
4 60.22 71.26 75.64 69.19 72.34 78.76
6 79.89 84.74 88.78 81.83 90.42 99.38
8 68.26 79.28 80.27 79.59 82.69 88.14
10 61.15 72.36 76.85 76.02 76.93 82.64
12 59.35 68.48 71.36 70.99 73.29 78.54
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Table 22: Percent swelling of formulations with HPMC K100M and polymer
combinations
Sampling
time(hr) F7 F8 F9 F10 F11 F12
1 22.56 24.45 24.48 21.27 22.26 22.47
2 34.73 39.57 38.46 33.76 36.38 35.64
3 56.26 60.84 56.37 49.27 54.18 50.15
4 74.28 79.36 76.72 70.56 76.45 70.84
6 89.27 92.34 99.64 90.36 99.48 95.42
8 84.38 88.34 92.27 81.16 91.65 85.37
10 75.74 78.38 82.64 75.64 86.24 80.25
12 68.34 70.37 78.84 73.34 82.56 75.32
All values represent mean ± standard deviation (SD)
Figure18: Percent swelling of formulations with HPMC K100M& combination
of polymers
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The percentage swelling obtained from the water uptake studies of the
formulations was shown in tables 21 and 22. The floating tablets containing HPMC
K4 , K15M and K100m  showed higher percent swelling  up to the first 6th hour but
could not maintain their matrix integrity up to 12 h. The floating tablets containing
HPMC K4M (F1 to F3) showed less percentage of swelling when compared with
HPMC K15M and HPMC K100M. The floating tablets containing HPMC K15M
showed less amount of swelling when compared with HPMC K100M This was due
to  increase in the viscosity of polymer, the swelling increases more and the drug
release will be decreased. So formulations containing HPMC K100M showed more
amount of swelling when compared with the other formulations. From the above
figures we can observe that formulations containing HPMC K100M has more
swelling properties from the other two polymers.
7.7 IN VITRO DRUG RELEASE STUDY:
Table 23: Cumulative Percentage drug release of formulations with
HPMC K4M (F1, F2, F3)
All values represent mean ± standard deviation (SD) n=3.
S. No Time(hrs) F1 F2 F3
1 0 0 0 0
2 1 21.22 19.97 18.50
3 2 33.13 29.13 26.70
4 4 50.56 47.00 40.36
5 6 73.18 64.46 62.83
6 8 99.91 73.61 75.07
7 12 - 99.33 92.88
Chapter 7 RESULT AND DISCUSSION
Dept of Pharmaceutics 81 J.K.K.Nattraja College of Pharmacy
Figure 19: Cumulative percentage drug release of formulations containing
HPMC K4M
From the above figure it can be observed that the polymer HPMC K4M has
controlled effect on the release of drug from the floating matrix tablet. The
percentage of drug release from formulations F1, F2 and F3 was 99.91, 99.33, 92.88
respectively and   difference in the drug release profile of various formulations was
due to the presences of different concentrations of polymer. Formulations F1 failed
to release the drug within the desired time. Formulation F2 and F3 release drug from
floating matrix above 12 hr. Formulation F2 was considered as best formulation
among all three formulations it showed good buoyancy properties (floating lag time:
78 sec & floating time > 12 hrs) and controlled the drug release for desired period of
time (12hrs).
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Table 24: Cumulative percentage drug release of formulations with
HPMC K15M
All values represent mean ± standard deviation (SD) n=3.
Figure21: Cumulative percentage drug release of formulations containing
HPMC K100M
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S. No Time(hrs) F4 F5 F6
1 0 0 0 0
2 1 17.98 15.17 14.83
3 2 29.98 24.41 20.57
4 4 47.55 41.41 36.70
5 6 63.52 55.66 50.41
6 8 76.57 69.32 61.12
7 12 95.84 85.33 83.81
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From the above figure it can be observed that the polymer HPMC K15M has
controlled effect on the release of drug from the floating matrix tablet. The
percentage of drug release from formulations F4, F5, and F6 95.84, 85.33 and 83.81
in 12 h respectively . Formulations F6, F7 and F8 failed to release the drug within
the desired time. The difference in the drug release profile of various formulations
was due to the presences of different concentrations of polymer. All these three
formulations floated for 12h. Formulation F4 was considered as best formulation
among all four formulations it showed good buoyancy properties (floating lag time:
80 sec & floating time > 12 hrs) and controlled the drug release for desired period of
time (12hrs).
Table25: Cumulative percentage drug release of formulations with HPMC
K100M
All values represent mean ± standard deviation (SD) n=3.
S. No Time(hrs) F7 F8 F9
1 0 0 0 0
2 1 11.99 10.10 9.29
3 2 23.71 15.17 14.89
4 4 40.68 29.87 23.71
5 6 57.02 47.52 44.52
6 8 72.97 60.95 57.72
7 12 90.47 74.01 61.55
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Figure21: Cumulative percentage drug release of formulations containing
HPMC K100M
` From the above figure it can be observed that the polymer HPMC K100M
has controlled effect on the release of drug from the floating matrix tablet. The
percentage of drug release from formulations F7, F8 and F9 are 90.47, 74.01 and
61.55 in 12 h respectively. Formulations F8 and F9 failed to release the drug within
the desired time. The difference in the drug release profile of various formulations
was due to the presences of different concentrations of polymer. All these three
formulations floated for 12h. Formulation F7 was considered as best formulation
among all three formulations it showed good buoyancy properties (floating lag time:
52 sec & floating time > 12 hrs) and controlled the drug release for desired period of
time (12hrs).
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Table 26: Percent drug release of formulations with combination of polymers
All values represent mean ± standard deviation (SD) n=3.
Figure 22: Cumulative % drug release of formulations containing  combination
of polymers
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S. No Time(hrs) F10 F11 F12
1 0 0 0 0
2 1 15.20 10.94 12.69
3 2 24.43 16.79 21.26
4 4 33.11 24.29 33.08
5 6 46.56 34.07 44.13
6 8 58.53 47.18 55.57
7 12 80.36 68.84 75.86
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From the above figure it can be observed that the polymer HPMC K4M,
K15M and K100M has controlled effect on the release of drug from the floating
matrix tablet. The percentage of drug release from formulations F10, F11, and F12
was 80.36, 68.84, and 75.86 in 12 h respectively. These are the formulations done
by combination of polymers.  Formulations F11,and, F12, failed to release the drug
within the desired time and difference in the drug release profile of various
formulations was due to the presences of different concentrations of polymer and
due to the high viscosity of the polymers. The cumulative percent of drug release
from various formulations and release coefficients values of the various models for
respective formulation were represented in table 16 and 20 respectively.
Formulation F10 was considered as best formulation among all three formulations
it showed good buoyancy properties (floating lag time: 75 sec & floating time > 12
hrs) and controlled the drug release for desired period of time (12hrs).
The cumulative percent of drug release from various formulations and
release coefficients values of the various models for respective formulation were
represented in tables 23 to 26 respectively. Fomulation F2 showed good drug release
and buoyancy time than all other formulations. The formulation F2 showed a
constant release in a controlled manner with 99.33%. Hence F2 was chosen for
kinetics studies.
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7.8 DRUG RELEASE MECHANISM:
7.8.1 RELEASE KINETICS
Table 27: Release kinetics of the optimum formulation F2
S.no Time
(hr)
√T Log
T
Cumulative
%drug
dissolved
Cumulative
%drug un
dissolved
Log
Cumulative
%drug
dissolved
Log
Cumulative
%drug un
dissolved
1 0 0 0 0 100 0 2.0
2 1 1.0 0 19.97 80.03 1.03 1.903
3 2 1.414 0.30 29.13 70.87 1.46 1.85
4 4 2.0 0.60 47.00 53.00 1.67 1.72
5 6 2.4 0.778 64.46 35.54 1.809 1.55
6 8 2.8 0.90 73.61 26.39 1.867 1.42
7 12 3.16 1.0 99.33 0.67 1.99 -0.17
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Figure 23: Zero order plot (F2) Formulation
Figure 24: First order plot (F2)
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Figure 25: Higuchi Plot  (F2)
Figure 26: Korsemeyer Peppas Model (F2)
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Kinetics of drug release
Table 27: Drug release kinrtics
Formulation Zero-order First-order Higuchi Krosmeyer peppas
R
2 N
F2 0.9877 0.8245 0.9818 0.6341 0.5062
The results of R2 for zero order and first order were obtained as 0.9877
and 0.8245. Based on that we confirmed that the optimised formulation followed
zero order  release.
The drug release was diffusion controlled as the plot of optimized
formulation F2 was found 0.9818 as regression coefficient in Higuchi plot.
From Korsemeyer- peppas’s  plot the release exponent value N was found as
0.506 and it was confirmed as the release of drug from formulation was founded as
anomalous non-fickian transport of diffusion.
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7.9 ACCELERATED STABILITY STUDIES
In any rationale design and evaluation of dosage forms for drugs, the
stability of the active component must be major criteria in determining their
acceptance or rejection.
During the stability studies the product was exposed to normal conditions of
temperature and humidity. However the studies will take a longer time and hence it
would be convenient to carry out the accelerated stability studies where the product
was stored under extreme conditions of temperature. In the present study, stability
studies were carried out on formulation F2.The tablets were stored at 40 ± 20 C
75 ± 5 % RH for a duration of three months.
The selected formulation was evaluated for stability studies. The formulation
were stored at 40°C at 75%RH for 3 months and analysed for their physical
parameters, drug content and friability after 3rd month the data were showed in table
no 29.
Table no 29: Physical parameters studies
Drug content (%) Hardness
(kg/cm2)
Friability (%)
After 1 month 99.33±0.17 4.1±0.3 0.45
After 2 months 99.12±0.15 4.0±0.42 0.46
After 3 months 99.12±0.15 4.0±0.42 0.46
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Table No 30: In Vitro Dissolution Studies
Time(hr) Initial 1st month 2nd month 3rdmonth
0 0 0 0 0
2 19.97 19.71 19.64 19.52
4 29.13 29.01 28.97 28.65
6 47.00 46.87 46.53 46.37
8 64.46 64.26 64.15 64.07
10 73.61 73.44 73.35 73.30
12 99.33 99.20 99.15 99.12
From the above tables (table no 29 & 30) it was observed there is no much
change in its physical properties and %drug release. Hence formulation(F2)
conformed stable.
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SUMMARY AND CONCLUSION
 The preformulation parameters like organoleptic properties, angle of repose,
bulk density, tapped density, Hausner’s ratio, carr’s index and
compressibility index of pure drug was evaluvated and complied with the
pharmacopoeial specifications.
 FTIR studies showed there was no interaction between drug and polymer.
 Gastro retentive floating matrix tablets of Losartan potassium were
successfully prepared with hydrophilic polymers like HPMC K4M, HPMC
K15M.,HPMC 100M.
 The formulated batches were evaluated for physicochemical parameters,
floating properties and dissolution profiles. From the evaluation results, it
was observed that the tablets contain the higher viscosity HPMC showed
long floating lag time when compared to tablets prepared with lower
viscosity HPMC. The physical properties like hardness, weight variation and
friability of majority of the batches complied with the pharmacopoeial
specifications. The drug content of all tablets was in the range of 95 – 100%.
 In vitro dissolution study of all the formulations was done in 0.1 N HCL. The
release rate was faster with lower viscosity grades of HPMC, probably owing
to less polymer entanglement and less gel strength and also to the larger
effective molecular diffusion area at lower viscosity as compared with higher
viscosity grades of HPMC.
 The tablets containing HPMC K4M (F2) showed satisfactory results with
short floating lag time (68 sec) total buoyancy time more than 12 h,
cumulative % drug release (99.33) and controlled drug release up to 12 h. So
F2 was taken for kinetic studies.
 The kinetic studies were carried for formulation F2 showed high regression
value of 0.9877 for zero order, 0.981 for Higuchi order (conforms
non- Fickian sustained release) and N value greater than 5 (conforms
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diffusion controlled) with complete release in 12 hrs made it to select as an
optimized formulation compared with other formulations.
 The accelerated stability was carried for F2 formulation and shown no much
change in physical parameters and cumulative % drug release. Hence
formulation F2 conformed as stable.
 Hence it was concluded that formulation F2 choosen as optimum
formulation.
 However In vivo studies and development of suitable packaging material
are made for future continuation of this experimental work.
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